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Abstract 
 
 
ACQUIRED EPIGENETIC AND CHROMOSOMAL CHANGES IN WOMEN 
TREATED FOR BREAST CANCER 
 
By Noran Anwar Aboalela, Ph.D 
 
     A dissertation submitted in partial fulfillment of the requirements for the degree of 
     Doctor of Philosophy at Virginia Commonwealth University  
     
Virginia Commonwealth University, 2014 
 
Major Director: Colleen Jackson-Cook, Ph.D. 
 Department of Pathology and Human and Molecular Genetics 
 
 
 
     Improved survival for women receiving chemotherapy for breast cancer (BC) has 
been accompanied by the development/persistence of psychoneurological symptoms 
(PNS) that compromise their quality of life. The biological basis for these PNS is 
unknown, but could reflect the acquisition of soma-wide chromosomal/epigenetic 
alterations. An important first step in testing this hypothesis is to determine if somatic 
genetic/epigenetic changes arise and persist following treatment.  To answer this 
question we longitudinally studied 71 women (ages 23-71) with early-stage BC and 
 
 
  
collected measures before chemotherapy (baseline), and 4 weeks (mid-chemo); six 
months (during radiation therapy for a subset of women); and one year following the 
initiation of chemotherapy.  Acquired lymphocyte chromosomal instability (scored by 
micronuclei frequencies [MNF]) showed a significant increase in post-treatment 
compared to baseline time-points (p<0.0001), with these increases persisting for at least 
one year following chemotherapy. Significant predictive associations were observed 
between MNF and tumor characteristics [luminal B (lower MNF; p=0.0182); triple 
negative (higher MNF; p=0.0446)], radiotherapy (higher MNF; p=0.0004),  the type 
of chemotherapy received (p=0.0463),  race (Caucasians > African Americans; 
p=0.0037), perceived stress levels (positive-association; p=0.0123), and cognitive 
flexibility domain measures (positive-association; p=0.0238). Genome-wide acquired 
methylation changes were also measured in peripheral blood cells, with 1265 sites 
showing significant differential methylation following chemotherapy. These sites were 
localized to open sea, shores, shelves, and CpG island sequences and included sites 
within genes involved in cell cycle, DNA repair, transcription regulation, signal 
transduction pathways, neuronal regeneration, and immunity. To determine if the 
genetic/epigenetic alterations acquired in peripheral blood cells correlated with those 
in tumor cells, BC tumors from 10 participants were analyzed using a genome-wide 
copy number/targeted mutations (CN/M) microarray. While no clear blood-tumor cell 
correlations were detected, genome-wide CN/M evaluations showed promise for 
stratifying tumors. Lastly, in an unrelated project studying a rare case of fetuses in fetu, 
methylation changes acquired in embryogenesis were shown to be influenced by both 
environmental and genetic cues.  In summary, acquired chromosomal/epigenetic 
 
 
  
alterations do arise following chemotherapy (and in embryogenesis). Further 
delineation of these acquired changes could increase our understanding of the 
biological basis for cancer-related side-effects and help to identify “at risk” individuals. 
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Chapter 1 
Background and Significance 
     Breast cancer (BC) is the most common invasive cancer in females, accounting for 
about 29% of all women’s cancers (Siegel et al 2014). Although BC is the 2nd most 
common cancer leading to death, advances in early detection and management have led to 
an increased survival rate (Jemal et al 2010). About 89% of diagnosed women are expected 
to survive at least 5 years after diagnosis (American cancer society 2013). However, the 
quality of survivors’ life is inevitably affected by short and long-term side effects of BC 
and its treatment (Mehnert et al 2007, Mehnert et al 2009, Winnie et al 2009, Byar et al 
2006). Anxiety (Badger et al 2007), depression (Badger et al 2007), cognitive dysfunction 
(Hurria et al 2007), sleep disturbances (Bender et al 2005), fatigue (Winnie et al 2009, Byar 
et al 2006), and pain (Winnie et al 2009) are the most common side effects observed in 
women who survive following BC treatments (Winnie et al 2009, National Institute of 
Health 2004, Kim et al 2008).  
     The clustering tendency of these psychoneurological symptoms (PNS) led researchers 
to question whether or not at least some of these symptoms might share a common 
biological etiology, and whether they could be collectively treated (Kim et al 2009, 
Misakowski 2006, Misakowski & Aouizerat 2007, Cleeland et al 2003). One of the most 
accepted theories for a shared biological mechanism is the cytokine-induced sickness 
behavior mechanism (Misakowski & Aouizerat 2007, Cleeland et al 2003, Dantzer 2001). 
Despite the animal studies and the clinical evidence that support this hypothesis (Konsman 
et 2002, Lee et al 2004, Cleeland et al 2003, Nozaki et al 1997, Capuron et al 2002, Raison 
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et al 2005), this mechanism has not been studied extensively in women treated for BC, nor 
has it been investigated with consideration of all the PN symptoms mentioned above. While 
some investigators have suggested mechanisms for a subset of these symptoms 
independently (Collado et al 2006, Ahles et al 2007), no effective prevention or treatment 
for the multiple symptoms associated with BC has yet been developed. Moreover, it 
remains unclear how long-term side effects persist even after the recovery from BC and its 
treatment, and from the inflammatory induction associated with BC and chemotherapy. 
These PN symptoms are observed in a major subgroup of BC survivors (Ahles et al 2007, 
Gatson-Johansson et al 1999, Janz et al 2007, Zabora et al 2001), but the reasons behind 
their occurrence in only a subgroup of survivors remains unknown. 
     Many factors could lead to the development of these PN symptoms in a major subset of 
BC survivors. Akin to the causes underlying most complex disorders, such as cancer and 
psychiatric problems, the factors influencing the development of PN symptoms, such as 
cognitive dysfunction and depression, are thought to include both environmental and 
genetic factors (Wichers et al 2009). Examples of environmental factors include the stress 
associated with the diagnosis and its treatment, nutrition, and BC therapeutic drugs. An 
individual’s genetic background could affect their susceptibility to develop the PN 
symptoms. Moreover, these factors could interact with each other, and could also trigger 
cellular biological changes such as inflammation, which have been evidenced to associate 
with sickness behavior. These observations raise many questions. In particular, how do all 
these factors interact and trigger biological changes, such as inflammation, that could lead 
to the development of PN symptoms in a subset of BC survivors? 
       A. Feinberg, who is one of the pioneers and leaders in the field of epigenetics, proposed 
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that epigenetics is an epicenter of modern medicine, serving to explain the relationships 
between environment, genetic background and disease (Feinberg 2007, 2008). Epigenetics 
is referred to as mitotically heritable modifications in gene expression and phenotype that 
do not result from changes in genetic sequences. It plays an important role in the 
development and differentiation of cells. Mounting evidence shows an additional major 
role of epigenetics in inflammation and in developing cancers and psychiatric diseases 
(Wierda et al 2010, Kristensen et al 2009, Pidsley 2011, Mehler 2009). Although epigenetic 
changes are known by their stable heritability, they have also been characterized by their 
plasticity and reversibility (Reik 2007, Narayan& Dragunow 2010). The heritability 
phenomenon could explain how long-term PN symptoms persist even after the recovery 
from BC and chemotherapy. The plasticity and sensitivity of epigenetics to genetic 
background, environment influences, and their interactions could explain why PN 
symptoms happen only in a subset of survivors. The reversibility of epigenetic changes 
makes them an attractive target for manipulation and drug therapies (Narayan & Dragunow 
2010).  
Cytokine-induced sickness behavior: “A biological mechanism at the cellular level” 
     One of the cellular biological mechanisms that is thought to have an important 
biological basis for the development of at least some of the PNS associated with cancer 
treatment is the cytokine-sickness behavior mechanism. It is thought that inflammation 
resulting from BC, or its treatment, has a role in symptom production (Cleeland et al 2003). 
From animal models, preclinical, and clinical evidence it is believed that sickness behavior 
requires an immune-to-brain communication. A cascade of pro-inflammatory cytokines is 
initially released by the action of macrophages. This released cascade then activates other 
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immune cells, such as lymphocytes and neutrophils. Peripheral cytokines could induce 
PNS through multiple pathways where cytokines are required to communicate with the 
brain. Cytokines could be produced not only by macrophages, but also by other cell types, 
such as tumor cells in cancer patients and nervous system cells (Reviewed in Cleeland et 
al, 2003). However, this mechanism alone cannot explain the occurrence of all these 
symptoms and their persistence, even after the recovery from BC and its treatments and in 
the absence of inflammatory induction. Therefore, inflammation could have a basic role in 
initiating the development of at least a portion of these symptoms. However, there must be 
more than one mechanism, perhaps - a series of interactive events - that occurs before and 
after inflammation to lead to the final observed outcome. Therefore, our hypothesis is that 
while inflammation may be one of the early biological changes leading to the development 
of these PNS, it is just one of a cascade of events that interact and together lead to the 
development of these short and long term symptoms (Figure 1). 
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Figure 1. Schematic illustrating the hypothesized mechanism(s) leading to PN 
symptoms associated with BC. Both environmental factors and genetic susceptibility lead 
to the development of BC in women before receiving BC treatments. BC and its treatment, 
in addition to the stress associated with the diagnosis, induce acquired biological changes 
such as inflammation activation and genetic changes involved in the inflammation process.  
Our hypothesis is that inflammation is one of the initiators of a cascade of events that arise, 
interact, and together lead to the development of PN symptoms. These events include 
acquired changes in epigenetic profiles, gene expression and chromosomal instability.  
Epigenetic changes are heritable on a cellular level, but are characterized by their plasticity 
and potential for reversibility. Thus, these changes are persistent, yet sensitive to genetic 
environmental interactions (E X G), making them a viable therapeutic target.  
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Environmental factors and genetic susceptibility: 
     Environmental factors include, but are not limited to, nutritional factors, the stress 
associated with BC diagnosis and its treatment, and BC treatments such as 
chemotherapeutic drugs, radiation and hormonal therapies. One important nutritional 
factor could be folic acid. Results of many studies have shown the important role of folate 
in the DNA methylation process. Folate provides the one-carbon units required in 
converting homocysteine to methionine, which is then converted to the universal methyl 
donor S-adenosylmethionine (Jacob R, 2000). Folate deficiency has been associated with 
birth defects and tumorogenesis (Jacob R. 2000, Blount BC et al. 1997). Moreover, folic 
acid concentration correlates significantly and inversely with frequencies of micronuclei 
in human lymphocyte cultures, indicating an association with genomic instability (Fenech 
M. 2007). Most importantly, the results of some studies suggest the role of folate deficiency 
in developing depression (Coppen and Bolander-Gouaille. 2005). Increasing evidence also 
links folate levels with inflammation (Mangoni A. 2006). Due to the role of folate in 
affecting methylation, gene expression and genomic instability, and its link with 
inflammation and depression, it is important to consider it in the complete final analysis of 
this study (part of full study;  results reported elsewhere).  
     Baseline “germline” or heritable genetic background influences could also affect a 
woman’s susceptibility to develop PN symptoms following treatment for BC. Background 
genetic influences involve the genomic sequence with its gene mutations, including those 
that might influence DNA repair mechanisms. In addition to germline genetic influences, 
acquired genetic changes could contribute to differential outcomes for women with BC. 
For example, tumor mutations, as well as baseline epigenetic modifications and 
 
 
7 
 
chromosomal instability levels, could play a role in a patient’s health outcome.  Therefore, 
both environmental factors and genetic background can lead not only to the development 
of BC, but also to the susceptibility of a woman to develop inflammation and, 
consequently, PN symptoms. For example, one mechanism where both genetic and 
environmental factors could be integrated is through the regulation of a methylation site 
overlapping with a single nucleotide polymorphism (SNP) that is associated with the 
development of a phenotype (Taqi MM et al.  2011).  
 
Breast Cancer:  
     BC is characterized by its heterogeneity and is highly challenging when it comes to its 
classification and treatments decisions (Polyak K. 2011).  Genetic and epigenetic research 
has helped in improving the ability to understand the development of BC, its classification, 
treatment decision and its prognosis.  
 
BC classification:  
     BC has traditionally been classified clinically and histopathologically (Westbrook and 
Stearns 2013, Viale G 2012). The tumor node metastasis (TNM) stage and tumor grade, 
along with the histopathological classification, remain included in the report and have been 
implicated in the prognosis of BC (Viale G 2012).  BC has also been subdivided by 
immunohistochemistry and/or fluorescence in situ hybridization (FISH) characterization 
according to the presence or absence of the human epidermal growth factor receptor-2 
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(HER2), estrogen (ER), and progesterone (PR) receptors. The results of gene expression 
microarray analyses have assisted in subdividing BC tumors into the molecular intrinsic 
subgroups (Basal like, Luminal subtypes, HER-2 enriched, and normal like) (Perou et al 
2000, Sorlie et al 2001, Sorlie et al 2003). The presence or absence of each of the three 
receptors helped in refining the molecular subtypes as; luminal A (ER+ and/or PR+; HER2-
), Luminal B (ER+ and/or PR+; HER2+), basal-like (ER-, PR-, and HER2-) , and HER2-
enriched (ER-, PR-, and HER2+)(Sinn P et al. 2013, Byler et al. 2014). The later 
classification has been extremely useful in directing the treatment and the prognosis of the 
cancer (Byler et al 2014). However, the hormone responsiveness doesn’t always determine 
the gene expression molecular subtypes. Many other genetic factors have been evaluated, 
underscoring the complexity of the tumors and the difficulties in accurately identifying the 
subtypes. In addition to the receptors noted above, BC tumors have been evaluated for 
different gene mutations, frequencies of mutations and also different types of mutations 
(non-sense or frame shift)(Byler et al. 2014). The heterogeneity and complexity when 
classifying BC is due to the tremendous number of genetic changes that could be implicated 
in its development. These changes include somatic gene mutations, copy number 
variations, alterations in gene expression and epigenetic changes. In Table 1 a summary is 
presented of some of the genes that have been found to show mutations or copy number 
aberrations in BC.   
 
    The oncotype DX, and MammaTyper, are some of the currently available tools specific 
for gene expression markers that were developed to aid in diagnosis, prognosis and therapy 
decisions relating to BC (Sinn et al. 2013). However, due to the inherent instability of 
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mRNA, which makes its use challenging, there is a need for more stable and reproducible 
tools. DNA methylation is an alternative tool. The stability and accessibility of DNA makes 
it a more attractive target, especially if whole blood cells could be used rather than the 
tumor tissue itself. Methylation will be more extensively discussed in the DNA methylation 
section.   
 
Treatment: 
     As more knowledge is being gained, there is a constant evolution of therapies given to 
patients with BC. Treatments include hormonal therapies, targeted biologic therapy, 
cytotoxic chemotherapy, and radiotherapy (Westbrook and Stearns 2013).  
 
 
Hormonal Therapies: 
     Several hormonal therapies are available and approved for treating BC. The selective 
estrogen receptor modulators (SERMs) -such as tamoxifen and raloxifene, and the third 
generation aromatase inhibitors (AIs), including anastrazole, exemestane and letrozole, are 
two classes of drugs commonly given to patients with BC (Westbrook and Stearns 2013).  
Tamoxifen is the most widely prescribed SERM given to women with early stage hormone 
responsive BC (Westbrook and Stearns 2013).  It is also effective in treating women with 
metastatic hormone receptor-positive BC and women having ductal carcinoma in situ 
(Rose & Mouridsen, 1984, Cuzick et al 2002, Westbrook and Stearns 2013).   
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Targeted biologic therapy: 
     Trastuzumab is one example of a targeted biologic therapy. This drug is a humanized 
monoclonal antibody (HMAB) given to suppress cell proliferation caused by the 
overexpression of the HER2 protein.   It works by binding specifically to the HER2 receptor 
(Westbrook and Stearns 2013). It is given in combination with chemotherapy and has led 
to a significant improvement for treating HER2 overexpressing tumors and a significant 
reduction in recurrence and mortality for women having this type of tumor (Piccart-
Gebhart et a 2005, Romond et al 2005, Slamon et al 2011, Westbrook and Stearns 2013).  
 
      Trastuzumab is not the only drug that targets HER2+ tumors. Pertuzumab also has been 
approved to be used in treating HER-2 + metastatic BCs by the European Medicine Agency 
in 2013 (Sabatier & Goncalves 2014). It could be used in combination with Trastuzumab 
and docetaxel. Moreover, lapatinib, which is a dual tyrosin kinase inhibitor could also be 
used in targeting both EGFR and HER2 (Zhu et al 2013).  
 
      Another example of a targeted therapy is Bevacizumab, which is HMAB that targets 
the vascular endothelial growth factor A (VEGF-A). (Westbrook and Stearns et al 2013). 
       
Cytotoxic Chemotherapy:  
The following are some of the cytotoxic drugs most often given to patients with BC. 
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Antimicrotubules Agents: 
Taxanes, including paclitaxel (Taxol) and docetaxel, are very effective chemotherapeutic 
treatments given to patients with both adjuvant and metastatic BC. They cause cell death 
by disrupting microtubule depolymerization and spindle formation during cell replication 
(Westbrook and Stearns 2013). 
 
Anthracyclines: 
Both doxorubicin and epirubicin are anthracyclins that have been widely used in treating 
BC. Although doxorubicin is widely used, the mechanism(s) for its effectiveness in 
preventing/reducing cancer cell proliferation is/are not fully known, with some 
investigators proposing that it induces cell apoptosis by inhibiting topoisomerase II, while 
others cite roles for DNA adduct formation, oxidative stress, ceramide overproduction 
and/or torsion-induced nucleosome destabilization as the causal means for this drug’s 
efficacy (Gewirtz 1999; Senchenkov , et al., 2001; Minotti, et al., 2004; Yang, et al., 2014, 
Westbrook and Stearns 2013). 
 
Cyclophosphamide: 
Cyclophosphamide is considered a backbone in BC treatment, which is incorporated 
into many adjuvant BC chemotherapeutic drugs. (Westbrook and Stearns 2013) 
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Carboplatin: 
Is a platinium analog, which induce double stranded DNA breaks. It has shown more 
efficacy in treating BRCA1- mutated tumors and triple negative breast cancers (Sikov et 
al 2014) 
 
Outcome:  
     Interestingly, patients treated with equivalent drugs show a significant variability in 
response and in survival outcomes (Polyak et al 2011, Westbrook and Stearns 2013). While 
the survival rate has improved significantly during the last few decades, it is time now to 
consider the quality of women’s life after surviving BC, along with improving their 
survival chances. One of our goals in this study is to understand how different types of 
treatments are affecting patients’ methylation patterns or causing chromosomal instability 
and how these latter changes relate to the acquired PNS affecting the patient’s quality of 
life.  
 
     There is a need for a discovery of tools that can be used in biomonitoring a patient’s 
response to a therapy (including its efficacy and toxicity) influenced by their genetic 
makeup. Advances in the genetic technology allowed the identification of candidate genes 
and SNPs that might associate with BC outcome.  Some studies have been conducted with 
the goal of identifying drug targets. Table 2 summarizes some of the candidate genes that 
are thought to be associated with the outcome when a patient is treated with a specific drug. 
While results from some studies support the associations between these genes and a 
patient’s response to treatment, others failed to confirm an association. Thus, insufficient 
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evidence is available to allow for unequivocal recognition of these associations on health 
outcomes in women treated for BC.  
 
Epigenetic modifications: 
     Epigenetics refers to the mitotically heritable modifications in gene expression and 
phenotype that do not involve any changes in the underlying DNA sequence (Russo et al 
1996). Epigenetic information is important for normal mammalian development and in cell 
differentiation (Reik 2007). It is not only involved in controlling gene expression, but also 
in the formation of heterochromatin, which can play an essential role in chromosome 
segregation and chromosomal stability (Herrera 2008). Feinberg et al, 2008, suggested 
epigenetics as a link between environment, genetic background, and disease. Rapidly 
growing evidence shows the major role of epigenetics in inflammation, developing cancers 
and psychiatric diseases (Wierda et al 2010, Kristensen et al 2009, Pidsley and Mill 2011). 
This process includes DNA methylation, histone modification, chromatin structure, and 
noncoding RNA-mediated regulation of gene expression (Kouzarides 2007)). Among these 
processes, DNA methylation and histone modifications are the most understood.  
 
DNA methylation: 
     DNA methylation involves the addition of a methyl group to position 5 of the cytosine 
pyrimidine ring (C) of a cytosine guanine dinucleotide (CpG) (Klose and Bird 2006). This 
process is catalyzed by the DNA methyltransferase (DNMT) enzymes (Klose and Bird 
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2006). DNA methylation is one of the most stable and well-characterized epigenetic 
mechanisms, which makes it an attractive area to focus on in our study (Jirtle and Skinner 
2007). Typically, in normal cells, promoter CpG islands are hypomethylated while 
repetitive DNA sequences in the genome are hypermethylated. Studies of genome-wide 
DNA methylation in cancer cells revealed that the methylation patterns can be reversed 
(Feinberg et al 2006). DNA methylation patterns in different tissues (normal and 
cancerous) including blood, are known to be sensitive to environmental insults such as age, 
alcohol intake and smoking (Table 3).  
 
    Genetic and epigenetic research has been very helpful in clarifying and understanding 
the development of cancer/BC (Tables 1, 4-6). Most of the genetic research has been 
performed using breast tumor tissues after the development of BC for purposes of 
classification, treatment decisions and prognosis prediction. Epigenomic research in cancer 
is a relatively new field. Studies of the role of epigenetics in cancer were initiated by 
searching for candidate genes that are known to be involved in breast and other tissues’ 
carcinogenesis using tumor tissues from patients with cancer. The recently available 
whole-genome methylation techniques allowed investigators to look for more global 
changes and search for epigenetic signatures that might add more information to the 
existing classification, with a goal of finding a better assessment of prognosis. Some 
current findings from DNA methylation studies on breast tissues from patients with BC are 
summarized in Table 4.  
     Researching the tumor itself is necessary for classification and treatment decisions for 
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the management of BC. However, an alternative approach that might be more powerful for 
evaluating a patient’s response to a treatment and to be able to more accurately predict 
systemic PN symptom outcomes could be through the study of peripheral blood specimens. 
Studies of methylation patterns in blood samples, especially circulating cell free DNA 
found in the serum or plasma, has been conducted with the purpose of finding biomarkers 
for breast cancer risk and diagnosis, or for prediction of treatment outcome and prognosis.  
DNA methylation patterns specific for cancer were found in the circulating cell-free DNA, 
which is released from dead cancer cells (Sidransky 2002, Van De Voorde et al 2012). 
DNA methylation biomarkers of BC found in the serum or plasma have been extensively 
reviewed by Van De Voorde et al. (2012). A summation of these findings is presented in 
Table 5.  Panels composed of two, three or more biomarkers have been developed (Van De 
Voorde et al 2012). It is important to note that methylation of many of these genes 
identified as biomarkers are not specific for BC and could be found in other types of tumors 
(Table 5). Problems of studying cell free DNA found in serum/plasma include the limited 
amount of DNA present, requiring the use of very sensitive techniques; possible 
contamination with DNA from whole blood cells; and limitations in following up acquired 
changes in methylation patterns associated with the treatment after the surgical removal of 
the tumor, since this cell free DNA is released from dead cancer cells.  
 
     Few studies have been done to investigate the association between BC -or cancer in 
general- and DNA methylation patterns in peripheral blood cells (PBCs).  The limited 
numbers of studies using PBCs reflects concerns regarding whether the methylation 
patterns in PBCs are suitable as a surrogate for changes arising in other tissues.  
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Investigators evaluated DNA methylation levels in PBCs of specific candidate genes as 
well as global genomic levels. Based on the limited number of available studies, global 
hypomethylation in PBCs has been associated with the presence of BC (Choi et al 2009). 
Also, methylation of specific loci have shown promise for use as markers for the presence 
of BC or an increased risk for developing BC (Iwamoto et al 2011, Wong et al 2010, 
Brennan et al 2012, Widschwendter et al 2008). Fewer studies have been performed to 
monitor chemotherapy effects on methylation of PBCs. Available data support the 
hypothesis that PBCs are a good representative cell for evaluation and could be used as a 
biomarkers indicating an increased risk for developing cancer, the presence of cancer, or 
changes acquired as a result of cancer (Table 6).  
 
 
     Cancer is a systemic disease involving many tissues (including peripheral tissues) rather 
than just the tumor by itself.  It becomes even more systemic when patients are treated for 
cancer,  since all their tissues are exposed to cyto/genotoxic regimens that are mainly toxic 
to the tumor, but also toxic to tissues within the human body as a whole. There are limited 
numbers of studies investigating the effect of treatments on methylation patterns in PBCs 
from patients with cancer.   The importance for using blood samples comes from the 
accessibility of blood, the non-invasive means for collection, and the ability to detect risk 
and follow-up acquired changes in methylation patterns longitudinally, allowing for 
biomonitoring progression and changes associated with specific treatments for prediction 
of outcome. Tumor tissues are not obtainable until after the development of the cancer and 
it is not possible to follow up changes in the tumor tissue after its surgical removal.  
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Chromosomal instability: 
 
     Micronuclei (MN) frequencies are widely used as an indicator of chromosomal 
instability. Studies in our lab and other labs showed that high frequencies of MN associate 
with aging, environmental exposures, and cancer (Table 7) (Fenech and Morley 1986, 
Fenech and Morley 1985, Jones et al. 2011). MNs are thought to form as a result of 
chromosome lagging at anaphase. They contain either whole chromosomes or 
chromosomal fragments that are not incorporated in the daughter nuclei at the completion 
of mitosis (Leach and Jackson-Cook 2001). Increased chromosomal instability has been 
observed in tumor tissues, peripheral blood of patients with cancer, and following the 
exposure of cells to chemotherapy and ionizing radiation (Table 7). Investigators have 
shown that cells with increased levels of methylation alterations are more susceptible to 
chromosomal instability (Herrera et al 2008). It has also been suggested that global DNA 
hypomethylation could lead to chromosomal instability, aneuploidy, and contribute to 
alterations in chromatin structure and cancer progression (Ulrich et al 2012).  
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Table 1: Summary of a subset of genes implicated in the development of BC:   
Type of genomic changes Genes References 
Somatic gene mutations:   
 Well established genes in BC development:   
 Genes  Involved in apoptosis, cell cycle regulation, and transcription regulation:  
 BRCA1 , RB1, TP53, PTEN, AKT1, CDH1, GATA3, PIK3CA Stephens et al 2012 * 
 Genes Involved in Signal transduction:   
 APC, ARID1A, ARID2, ASXL1, BAP1, KRAS, MAP2K4, MLL2, MLL3, NF1, SETD2, SF3B1, SMAD4, AND STK11  
 A recently identified group of genes:  
 ARIDIB, CASP8, MAP3K13, MAPK2K13, NCOR1, SMARCD1, and CDKN1B   
   
   
 Well established genes in BC:  
 RB1, TP53, PTEN, AKT1, CDH1, GATA3, PIK3CA, MLL3, MAP3K1, CDKN1B  
 Mutation in 3 genes occur in > 10% incidence across all BC: The Cancer Genome Atlas 2012*  
 TP53, PIK3CA, and GATA3  
 Novel genes:  
 TBX3, RUNX1, CBFB, AFF2, PIK3R1, PTPN22, PTPRD, NF1, SF3B1, and CCND3  
   
Copy number aberration:    
   
 Amplification of regions containing PIK3CA, EGFR, FOXA1, and HER2 correlated with different mRNA subtypes The Cancer Genome Atlas 2012 * 
  Deletion of regions containing MLL2, PTEN , RB1, and, MAP2K4  correlated with different mRNA subtypes  
   
   
 Used the MIP probe and identified 19 CNI that discriminate recurrence risk among early stage BC  Thompson et al 2011 
  The data suggest that specific CNI might promote or limit tumor spread in some cases   
   
* Reviewed by Byler et al 201 
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Table 2: Summary of candidate genes potentially related to BC outcome in response to a treatment*   
Agent Proposed Outcome Candidate Variant Genes 
Hormonal Therapy:   
Tamoxifen Poorer outcome CYP2D6 poor metabolizers, SULT1A1, UGT2B15, ABCB1, ESR1  
 Increased likelihood of tamoxifen discontinuation CYP2D6 extensive metabolizers 
 Decreased hot flashes ESR2 
      
Targeted biologic therapy:   
Trastuzumab Better outcome  Fc gamma RIIIa-158V/V  
      
Cytotoxic chemotherapy:   
Antimicrotubules: Docetaxel Increased myelosuppression SLCO1B3 
   
Anthracyclines: Doxorubicin Better outcome  ABCB1 C354T, MPO, NOS  
 Greater reduction of tumor burden , increased neutropenia CBR311A  
   
Cyclophosphamide Better outcome  CYP2B6 
 Poorer outcome  ALDH1A1 
 Poor pathological CR, reduced risk of hematologic toxicity GSTP1 
   
 
*Adapted from review by Westbrook et al.,  2013 
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Table 3: Examples of environmental influences on DNA methylation in blood and other tissues in health and disease   
Environmental influences Tissue Tool(s) used for assessment Finding References 
  WBC, Lung & other   
Found age-dependent DNA methylation signatures 
of genes in WBC and  in other tissues and were 
  
  solid tissues Illumina Infinium 27k 
independent of disease state, sex, tissue and cell 
type. 
 Teschendorff 
Aging (normal and cancer) Goldengate assay  et al 2010 
  Cervix, mesenchymal stem   
The signature is present in preneoplastic conditions 
and might be  associated with carcinogenesis 
 
   cells  and ovarian cancer      
          
          
Aging  WBC, CD4+ T cells, CD14+ Illumina Infinium 27k  
Identified aging aDMRs signatures with a 
multitissue phenomenon.  
Rakyan et al 2010 
   monocytes, buccal cells      
          
          
Alcohol intake, folate  BC tumor  GoldenGate BC DNA methylation profiles are associated with  Christensen et al 
and tumor size     alcohol & folate intake 2010 
          
          
Alcohol intake  WBC LC-ESI-MS/MS for 5-mdC 
Among controls alone or combined with cases of 
BC, alcohol 
Choi et al 2009 
    Pyrosequencing for LINE-1   intake was inversely associated methylation levels   
          
          
Smoking WBCs  Illumina Infinium 27k,  
Identified a single locus (F2RL3) differentially 
methylated 
Breitling et al  
     Mass spectrometry    between exposure groups 2011 
    & Sequenom EpiTYPER 
The gene was fully replicable in an independent 
sample  
  
       
Associated differentially methylated regions (aDMRs)       
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Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)   
   
Table 4: Methylation patterns in BC tissue tumor:  
Tool(s) Findings References 
   
Genome Atlas Network 
BC can be classified into several groups that are related to the cellular origin of the tumor and 
are different than current gene expression classification, with some  overlap with intrinsic 
subgroups 
The cancer Genome Atlas 2012   
(1) 
   
MeDIP* (Familial BC) Studied familial BC and identified distinct profiles defined by mutation status Flanagan et al 2010 
Validation by pyrosequencing and 
epityper 
Identified a distinct subtype of BRCA tumors based on their methylation profile  
      
   
Illumina 27 k  Methylation of 4 genes is affected by ER/PR status Li et al 2010           (2)  
      
   
Illumina 27 K  Identified a group of genes where their methylation is associated with relapse free survival Hill et al 2011        (2) 
      
   
Illumina 27 k  
Identified a methylator phenotype that is associated with lower risk of metastasis and better 
survival rate  
Fang et al. 2011     (2) 
      
   
Illumina Golden Gate methylation  
Tumor grade, size, estrogen and progesterone receptor status, and triple negative are 
associated with altered methylation 
Christensen et al 2010 
Validation by Sequenom EpiTYPER Association with race, and tumor size.   
 * Methylaed DNA immuneprecipitation (MeDIP) 
(1) Reviewed by Byler et al 2014 
(2) Reviewed in Szyf , 2012 
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Table 5: Summary of biomarkers for BC based on studies of cell free DNA from serum/plasma*:  
Type of Biomarkers List of genes 
Biomarkers related to BC:  
Markers involved in cell cycle regulation BRCA1, GSTP1, RASSFA, APC,RAR-β , MGMT, P16 INK4A , P14ARF , 14-3-3-σ, TMS1, Cyclin D2 
Markers related to hormone receptor  ESR1, ESR2, PR 
Markers involved in cell adhesion CDH1, TIMP-3, Slit2 
  
Biomarkers associated with poor prognosis RASSF1A, APC , GSTP1, BRCA1, 14-3-3-σ, PITX2, P16INK4A, ERB, RARβ2,  
  
Biomarkers for response to treatment  
 Surgery and Tamoxifin  Surgery significantly reduced the methylation of MGMT, PAX5, and RARB2, but not MDGI 
 Tamoxifen had a more pronounced effect on MDGI 
 Methylation of PR PROX was equally affected by surgery and tamoxifen  
 Methylation of ESR1 and MSH1 was initially reduced by surgery, but increased during tamoxifen treatment 
Neoadjuvant chemotherapy Methylation levels of RASSF1A  in serum may indicate tumor shrinkage  
  could be used in monitoring response during neoadjuvant chemotherapy 
  
Markers found in other types of tumor Lung: BRCA1, APC, RAR-β, P16,  
 Ovarian: BRCA1, RASSF1A, Slit2 
 Liver:GSTP1, Hepatocellular cancer: Slit2 
 Prostate: GSTP1, RASSF1A, Slit2, ER 
 Bladder: RASSF1A, 
 Stomach: APC, Gastric cancer: CDH1, Gastrointestinal tract: P16, 14-3-3-σ,  
 Colorectal: APC 
 Glioblastoma: RAR-β, P14ARF, TIMP3, Glioma:MGMT, P16, Neuroblastoma: TMS1 
 Lymphoma: P16, Cyclin D2,  Multiple myeloma: P16 
 Cervix: P14ARF 
 Cholangiocarcinoma: TMS1 
 Pancreas: TMS1 
 Melanoma: ER 
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  Endometrial: PR 
* Adapted from reviewed by Van De Voorde et al.,  2012 
Table 6: Methylation biomarkers in WBCs for  different types of cancer     
  Tissue/type of tumor Tools Finding References 
Gene:         
 IGF2 PBL / (P&D CM)  Imprinting analysis LOI at IGF2 in PBL could be a valuable predictive marker of risk for CRC Cui  et al 2003 
          
IGFE PBL 
Quantitative hot-stop 
PCR  LOI at IGFE in PBL as a hereditary risk factor for colon neoplasia  
Cruz-Correa 
et al 2004 
    for imprinting analysis     
          
49 genes * WBCs/BC MethylLight assay DNA methylation in WBCs provides a good prediction of BC risk 
Widschwendt
er et al 2008 
          
 BRCA1 promoter WBCs/BC 
Methylation specific 
qPCR  BRCA1 promoter methylation in WBCs is significantly associated  
Iwamoto et al 
2011 
      with risk of BC tumors with BRCA1 promoter methylation   
          
          
BRCA1 WBCs/BC 
MethylLight and (MS-
HRM) BRCA1 methylation in WBCs identifies a small group of women  
Wong et al 
2010 
      in the population who have increased risk for an early-onset BC   
          
 ATMmvp2a & 
ATMmvp2b WBCs 
Bisulfite 
pyrosequencing DNA methylation at ATM  could be a marker of BC 
Brennan et al 
2012 
/ LINE-1     No differences in LINE-1 between cases and controls   
Global:          
  WBCs/ BLC Illumina 27k  DNA methylation profiles  associate with risk of BLC 
Marsit et al 
2011 
          
          
  WBC/ BLC  HPCE & Hpa II D&D Hypomethylation associate with increased risk of developing BLC 
Moore et al 
2008 
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  WBC/ (HNSCC) Modified version  of DNA hypomethylation is associated with HNSCC, 
Hsiung et al 
2007 
     CBRA of LRE1 sequence  Complex relationship with the known risk factors    
      ex: smoking and folate intake    
          
  WBCs /  PaC 
GoldenGate (phase l) & 
ICVC  DNA methylation signature that can  detect (PaC) 
Pedersen et al 
2011 
     (phase ll)     
          
  WBCs/ OC Illumina 27k  DNA methylation signature that can detect or predict risk of OC 
Teschendorff 
et al 2009 
          
  WBCs /BC 
(LC-ESI-MS/MS) for( 5-
mdC) Global DNA hypomethylation  is associated with development of BC 
Choi et al 
2009 
    
Pyrosequencing for( 
LINE-1)      
          
  WBCs/BC MethylLight DNA methylation levels in WBC from control girls are associated Wu et al 2011 
    Pyrosequencing  with family history of BC   
          
Sat2M1:         
  WBCS/BC tumor/  & MethylLight  Sig. correlation in methylation of Sat2m1 between the 3 tissue types 
Cho et al 
2010 
  adj. normal tissue   Sig. differences  in methylation of Sat2M1 between cases and controls   
          
LINE-1:          
  WBCs / RCC 
Pyrosequencing in 
triplicate,  High LINE-1 methylation levels were positively associated with RCC 
Liao et al 
2011 
    
& averaged across 4 
CpG sites The association was stronger with current smokers than with    
      former / never smokers   
          
  Lymphocyte/BLC  Pyrosequencing  LINE-1 hypomethylation is associated with BLC risk among non-smokers  
Cash et al 
2012 
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      Reduced LINE-1 methylation in current smokers with high    
      cytochrome index   
          
  WBCs/ BLC Pyrosequencing  Line-1 hypomethylation is associated with BLC risk;  
Wilhelm et al 
2010 
      especially among women    
          
          
BC and 
Chemotherapy Blood Mononuclear cells Illumina 450k  8 CpG sites were hypomethylated in women treated with chemo  Smith et al  
      as compared to control (not treated) women;  2014 
      After radiation only 4 CpG sites remained   
     
Methylation at these sites was associated with inflammation but not with 
fatigue   
          
* Lymphocyte (PBL)         
Quantitative analysis of methylated alleles (QAMA)       
 loss of imprinting (LOI) 
Colorectal cancer (CRC)         
49 GENES included a) 19 ERT genes b) 4 genes ER-a target genes(diffrentially methylated based on hromone receptor status) c)20 PCGT genesmore likely have a promoter DNA 
hypermethylation in cancer . D) 6 genes that are known to be methylated in BC (MBC)  
proximal and distal colonoic mucosal (P&D CM)        
 Head and neck squamous cell carcinoma (HNSCC)       
 Pancreatic adenocarcinoma (PaC)       
Bladder Cancer (BLC)         
Ovarian Cancer(OC)         
Renal cell cancer(RCC)         
Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)    
Methylation Sensitive-High Resolution Melting (MS-HRM)     
 high-performance capillary electropheresis(HPCE)       
combined bisulfite restriction analysis (CBRA)       
 digestion & densitometry (D &D)       
Illumina. custom VeraCodemethylation (ICVC)       
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Table 7: Summary of previous studies related to BC or its treatment evaluating MN frequencies in 
peripheral blood lymphocytes  
 
Topic  
 
References 
Breast Cancer Effects 
Higher MN frequencies  in untreated women with breast cancer  irrespective of 
smoking  and aging  
 
Santos et al., 
2010 
Significant differences in MN frequencies at baseline between patients with breast 
cancer and controls 
 
Cardinale, et al. 
2012 
 
Chemotherapy Effects: 
In vitro study showing variation in response to doxyrubicin-induced MN between 
lymphocyte cell lines; Polymorphism in the GSTP1 gene was associated with an 
increased MN frequency 
 
Ramos et al., 
2011  
In vitro study showing a significant increase in MN frequencies in breast cancer cell 
lines following exposure to doxyrubicin; methoxyamine alone did not significantly 
increase MN frequencies;  use  of both methoxyamine and doxorubicin significantly 
increased levels of MN frequencies (combination higher than single exposure values) 
 
Guerreiro et al., 
2013 
In vivo study showing MN frequencies in lymphocytes and buccal mucosa cells from 
children with malignant tumors (various types) increased significantly following 
chemotherapy 
Minicucci et al ., 
2008 
In vivo longitudinal study (1 year) showing MN frequencies increased significantly 
after one cycle of chemotherapy and remained increased for 2 months after the 
completion of chemotherapy (Cisplatin); MN frequencies also correlated  with the 
cumulative dose of Cisplatin  and with Cisplatin-induced nephrotoxicity 
Elsendoorn et al 
2001 
Radiation Effects: 
In vivo  study showing MN frequencies increased significantly during radiation and 
further increased immediately following the completion of radiation; MN frequencies 
not influenced by age  
Jagetia et al., 
2001 
Higher MN frequencies during radiotherapy; while decreases in frequency were 
observed  6 months and one year after radiotherapy, MN frequencies  did not return to 
pre-therapy level in the majority of patients;  older subjects (ages 75-80; also had 
more advanced tumors) showed higher MN frequencies than younger subjects (ages 
57-70) 
Gamulin et al., 
2010 
In vivo studies showing radiation-induced MN  frequencies  were correlated with dose 
and quality of occupational, medical, accidental, or therapy-related radiation 
Vral et al., 2011  
 
In vitro study showing significant increase in MN frequencies in cells exposed to 
ionizing radiation, with the difference in frequency responses of patients with breast 
cancer compared to controls exceeding the differences observed at baseline   
Cardinale, et al., 
2012 
 
Chemotherapy and Radiation Effects: 
In vivo study showing an increased frequency following radiation alone and following 
radiation in combination with chemotherapy regardless of age or smoking 
 
Milosevic-
Djordjevic et al., 
2011 
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In vivo longitudinal study (18 months) showing MN frequencies increased after 
radiation  (20 patients received radiation)  but not after chemotherapy (only 9 out of 
20 patients received and were assessed after chemotherapy) 
MN frequencies were not significantly correlated with tumor size, receptor status, 
nodal status, family history of cancer, age, or smoking habits  
Aristei et al., 
2009 
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Hypothesis, goals, aims, study design and significance of the present study: 
Hypothesis: 
     Treatment advances have resulted in improvements in survival for women diagnosed with 
breast cancer, but many of these survivors report acquiring persistent adverse side effects 
following treatment. The etiology of the observed PNS is not fully known. Chemotherapy, or the 
tumor itself, induces short-term effects and long-term PN effects through a series of events and 
interactions, which result in acute and chronic biologic changes, where some could be persistent 
for years after completing a successful treatment. We offer the hypothesis that inflammatory 
activation is an early step in a cascade of biological changes leading to genomic and/or epigenetic 
alterations that contribute to PNS. Alternatively, epigenetic alterations may occur first, leading to 
inflammatory activation. These epigenetic changes could also lead to chromosomal instability. 
Each of these genomic/epigenetic factors, acting either singly or in concert, could contribute to the 
development/persistence of PNS since they would provide a means for “remembering” the 
biological effects after chemotherapy and have plasticity to explain responsiveness to 
environmental exposures (as well as G x E interactions). They also have the potential for 
reversibility, with the latter attribute being important for the potential development of therapeutic 
interventions (Figures 1 & 2). 
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Figure 2: The Strength of investigating epigenetic mechanisms: Epigenetic mechanisms 
provide a means for “remembering” the biological effects after chemotherapy and have plasticity 
to explain responsiveness to environmental exposures (as well as G x E interactions). They also 
have the potential for reversibility, with the latter attribute being important for the potential 
development of therapeutic interventions. 
 
Acquired epigenetic/chromosomal changes in women with breast 
cancer are associated with chemotherapy and the acquisition/
persistence of psychoneurological symptoms. 
Conclusions 
Background, Hypothesis and Aims 
Molecular Cytogenetics Laboratory 
Department of Pathology 
What are the factors that associate with MNF ?  
Did leukocyte methylation patterns change with 
chemotherapy? 
Supported by NIH grant R01 NR012667 (D Lyon and C Jackson-Cook, PIs). 
Figure from Illumina 
Website 
(B) 
 
• The study showed 6 predictors of MNF: Visit, type of tumor, chemotherapy, radiation, race, 
& stress. 
• Micronuclei frequencies in women diagnosed with breast cancer increased after exposure 
to chemotherapy and radiation. Also, differences were observed based on the type of 
chemotherapy  received (AC higher than TC or TCH). 
• Decreases in MNF were observed after 1 year following treatment, but did not return to 
baseline levels. 
• White women had overall higher MNF as compared to African American women. 
• Women with more stress had higher MNF. 
• Methylation alterations were acquired in response to chemotherapy, with hypomethylation 
changes being seen most often; especially following AC. Changes were observed for 
multiple types of sequences for both AC and TC and were predominantly associated with 
RNA transcripts. 
 
 
Continuation of these studies may allow for the recognition of consistently acquired genomic/epigenomic 
alterations that contribute to the development and/or persistence of PNS in women treated for breast cancer. This 
knowledge could be used to identify  biomarkers for predicting a woman s risk for developing PNS, thereby 
empowering her to make informed decisions regarding treatment options. These studies may also provide the 
foundational basis for the development of targeted interventions to possibly alleviate or reverse the PNS 
associated with breast cancer and its chemotherapy.   
Women with HER2+ expression/treatment showed lower MNF. A significant increase in MNF 
was observed in the women following chemotherapy (V2) and following radiation (V3). A 
significant difference in MNF was also observed between chemotherapy regimens at V2:  AC > 
TC or TCH. 
(A) Variation in changes in methylation patterns were noted among patients. (B) Acquired 
hypomethylation was seen more often in women receiving AC vs TC.  (C) A trend toward more 
hypomethylation alterations involving CpG islands was observed with AC.  For both chemo 
types the majority of changes occurred in open sea  sequences, followed by CpG shores and 
islands. (D) The majority of both AC & TC hyper- and hypomethylation changes occurred in RNA 
coding sequences. Using a FDR of 1%, 15,939 differentially methylated regions (3.4% of total 
array sites) were observed at mid-chemo compared to baseline time points. Specific genes that 
were noted to show altered patterns included (but were not limited to) those involved in DNA 
repair, transcription regulation, signal transduction pathways, and neuronal regeneration. 
    Treatment advances have resulted in improvements in survival for women diagnosed with 
breast cancer, but many of these survivors report acquiring persistent adverse side effects 
following treatment. These psychoneurological symptoms (PNS) include cognitive 
dysfunction, depression, anxiety, fatigue, sleep disturbances, and pain. The etiology of these 
PNS is not fully known. We offer the hypothesis that inflammatory activation is an early step 
in a cascade of biological changes leading to genomic and/or epigenetic alterations that 
contribute to PNS. Alternatively, epigenetic alterations may occur first, leading to 
inflammatory activation. These epigenetic changes could also lead to chromosomal 
instability. Each of these genomic/epigenetic factors, acting either singly or in concert, could 
contribute to the development/ persistence of PNS since they would provide a means for 
remembering  the biological effects after chemotherapy and have plasticity to explain 
responsiveness to environmental exposures (as well as G x E interactions). They also have 
the potential for reversibility, with the latter attribute being important for the potential 
development of therapeutic interventions.  
(A) (C) Types of sequences with baseline to mid-chemo 
methylation alterations*  
Hyper with 
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TC 
Hyper with 
AC 
Hypo with 
AC 
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(D) Methylation alterations associated with coding 
RNA* 
FDR = 5% 
(B)  Total methylation 
changes* 
 TC (n=12) 
 AC (n=7) 
MNF increase significantly following the initiation 
 of treatments as compared to baseline levels.  
              Factors predictive of MNF: 
1. Visit (p<.0001): MNF increase with treatment 
2. Chemotherapy (p=.0213): MNF highest in AC treated 
patients 
3. HER2+ (all received trastuzumab)(p=0.0012): MNF 
lower    
4. Radiation (p=.0185): Subset of women treated 
5. Race (p=.0129): C women had higher MNF than AA 
6. Stress (p=.0044): Women with more stress had higher 
MNF 
Goal, Study Design, Aims,  and Methods 
Specific Aims: 
The primary aims of this study were to 
collect blood specimens from women 
having a diagnosis of breast cancer 
and  longitudinally determine: 
1. The frequency of acquired 
chromosomal instability and genome-
wide epigenetic changes present at 
baseline and following treatments. 
2. The relationship between acquired 
chromosomal and/or epigenetic 
alterations and the development/
persistence of PNS. 
Investigate the biological basis for the development of  PNS associated with 
chemotherapy, or the cancer itself, in women treated for BC. 
Goal : 
Longitudinal+Study+Design:+(5+4me+points) 
(A) 
Methods: 
Aboalela N1, Lyon D2,, Elswick R2, York TP 1, Kelly DL2, Jackson-Cook C1,3 
1Department of Human and Molecular Genetics, 2School of Nursing,  3Department of Pathology, Virginia 
Commonwealth University, Richmond, VA 
! ! ! ! ! ! ! ! ! ! !
! ! !
Demographic,
,
A,American,, N=22, !! Caucasian, N=51, !!
! ! !
Measure, TAC! TC! TCH! TAC! TC! TCH! Total!
! ! !
!! (n=10),! (n=6)! (n=6)! (n=30)! (n=16)! (n=5)! (n=73)!
! ! !
Income, !! !! !! !! !! !! !!
! ! !
Less!than!30,000! 5!(22.73)*! 4!!(18.18)!!! 3!(13.64)! 6!!(11.76)! 1!!!(1.96)! 0! 19!!!!!(26.03)!
! ! !
30,000?59,999! 3!(13.64)! 2!!(9.01)! 3!(13.64)! 6!!(11.76)! 1!!!(1.96)! 0! 15!!!!!(20.55)!
! ! !
60,000?89,999! 1!!!!(4.55)! 0! 0! 7!!(13.73)! 8!(15.69)! 3!!!(5.88)! 19!!!!!(26.03)!
! ! !
90,000+! 1!!!!(4.55)! 0! 0! 11(21.57)! 6!(11.76)! 2!!!(3.92)! 20!!!!!(27.40)!
! ! !
Current,Smoking,
Status, ! ! ! ! !
!
!!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Yes! 2!!!(9.01)! 3!!(13.64)! 2!!(9.01)! 5!!!(6.94)! 2!(2.77)! 1!!!(1.39)! 15!!!!(20.83)!
! ! !
No! 8!(36.36)! 3!!(13.64)! 4!(18.18)! 25(34.72)! 13!(18.06)! 4!!!(5.56)! 57!!!!(79.17)!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Current,Ethanol,
Consumption, ! ! ! ! ! ! !!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Yes!
3!(13.64)! 1!!!(4.55)! 2!!!(9.01)! 19(37.25)! 12!(23.53)! 4!!!!(7.84)! 41!!!(56.16)!
! ! !
No! 7!(31.82)! 5!!(22.73)! 4!(18.18)! 11(21.57)! 4!!!!!(7.84)! 1!!!!(1.96)! 32!!!!(43.84)!
* Number (%) 
!
!
!
!
!
! !
!
!
! !
!
!
!
!
!
!
! !
!
!
! !
!
!
!
!
!
!
! !
!
!
! !
!
!
!
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Goal:  
Investigate the biological basis for the development of the clustering PNS associated with 
chemotherapy, or the cancer itself, in women treated for BC. 
 
Specific aims: 
The primary aims of this study were to collect blood specimens from women having a diagnosis 
of BC and longitudinally determine: 
1) The frequency of acquired chromosomal instability and genome wide methylation changes 
present at baseline and following treatments. 
2) The relationship between acquired chromosomal alterations and the development of PNS. 
 
Overall study design: (Note: This thesis is a part of a larger study design) 
     In order to understand the epigenetic and the chromosomal instability changes, and their role 
in developing PNS, which are associated with BC and its treatments, we designed a longitudinal 
study to follow a total of 76 women treated for BC at 5 time points within a two-year time period. 
For the facet of the study reported in this thesis, acquired changes in PBCs methylation patterns 
and frequencies of MN formation in binucleated lymphocytes were examined at 4 time points: 
before the initiation of chemotherapy, at the 4th chemotherapy, 6 months after the initiation of 
chemotherapy (at which time some women are receiving radiation therapy), and 12 months after 
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the initiation of chemotherapy. Because it is not completely clear whether the tumor itself or the 
treatment is initiating the development of these symptoms, we initiated copy number assessments 
in tumor tissues obtained from a subset of women who provided their consent to have their tumor 
specimens evaluated. 
 
The tissue sample choice: 
     In order to identify acquired epigenetic changes/chromosomal instability associated with the 
development of PN symptoms observed in a subset of women treated for BC, one would think of 
the brain tissue as one of the most affected or permanently affected tissues. While acquired 
epigenetic changes in brain cells are likely to be associated with some of the observed symptoms, 
such as cognitive dysfunction, they would not be anticipated to be clearly associated with all of 
the observed symptoms, such as fatigue. Also, it is not possible to sample brain tissue from living 
individuals (especially since multiple brain areas would need to be evaluated to most accurately 
reflect the neural tissue changes that might arise).  
 
     Inflammation, which results from BC, and its treatment, has been suggested to have a role in 
PNS production (Konsman et al 2002, Lee et al 2004, Cleeland et al 2003). Because white blood 
cells (WBCs) are involved in the inflammatory process, blood samples are optimal. As mentioned 
earlier, animal models, preclinical and clinical evidence showed that sickness behavior requires an 
immune-to-brain communication, which involves cytokines and (WBCs) (Cleeland et al 2003). 
Therefore, we believe that blood samples are one of the best sample choices to be investigated in 
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our study. Moreover, we are investigating acquired changes associated with chemotherapy. Thus, 
blood cells are one of the first cells to be exposed and affected by the therapy. Indeed, leukocytes 
could reflect one of the earliest acquired epigenetic changes associated with BC chemotherapy and 
inflammatory induction, which happen before triggering other changes that cause the occurrence 
of the permanent changes in brain cells. Blood samples are easily obtained and all parts of our 
study could be easily performed on this type of tissue, including inflammatory biomarkers 
measurement, acquired epigenetic changes, gene expression and MN frequencies assessments. 
Furthermore, for future implications, if epigenetic signatures or MN assessments could be used to 
estimate an individual’s risk or could be treated, this sample will be the easiest to obtain and follow 
up. 
 
     Another sample that would be interesting to look at is cells from the tumor cells themselves. 
The tumor may be the source that initiates a cascade of changes, including inflammation, and 
acquired epigenetic changes in other tissues such as WBCs. Cytokines could be produced not only 
by immune cells, but also by other cell types such as the tumor cells in cancer patients (Cleeland 
et al 2003). It remains unclear how chemotherapy affects women and associates with the 
development of PNS in a subgroup of women treated for BC. Thus, it is important to investigate 
not only blood samples, but also the tumor tissue itself. It is possible that the tumor cells define or 
are related to the susceptibility of women to develop PNS as a result of chemotherapy.  
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Significance:   
     The results from this study will enable us to gain a better understanding of the biological basis 
for the development and persistence of PN symptom in women with BC, with the hope of 
enhancing the quality of survivors’ lives. With advances in the pharmacology of epigenetics, if the 
development of PN symptoms could potentially be detected at an earlier point, they might be 
prevented or alleviated through treatment. Alternatively, the results of this study could provide a 
basis for recognizing women who are most “at risk” for developing PNS, thereby allowing them 
to make more informed decisions regarding their therapy options. This study is the first of its kind 
where multiple biological mechanisms and symptom assessments are followed during the 
treatment course with a hope of helping BC survivors to live with a better quality of life. 
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Chapter 2 
 
 
Acquired Chromosomal Changes in Women Treated for Breast Cancer and their 
Association with the Development of Psychoneurological Symptoms 
 
 Micronucleus frequencies in lymphocytes 
 
 
 
Introduction 
 
     Breast cancer is the most common invasive cancer in females, accounting for approximately 
29% of all women’s cancers (Siegel et al, 2014).  According to estimates from the American 
Cancer Society, about 12.3% of women in the US will develop breast cancer during their lifetime 
(American Cancer Society, 2013).  Due to advances in early detection and management, 
approximately 89% of women diagnosed with breast cancer will survive for at least 5 years 
(American Cancer Society, 2013). Unfortunately, these advances in survivorship have been 
accompanied by the acquisition of treatment-related adverse side effects that can compromise the 
quality of life for many women who receive treatment for breast cancer. These side effects, 
which include anxiety (Badger et al. 2007), depression (Badger et al. 2007), fatigue (Berger et al. 
2010), cognitive dysfunction (Wefel et al 2011) , sleep disturbance (Lee et al 2004), and pain 
(Utne et al 2010, Valeberg et al 2008), are collectively referred to as psychoneurological 
symptoms (PNS) and can persist for years after treatment.   
 
     The biological basis for the genesis of PNS in women treated for breast cancer is not known.  
The results of some cross sectional studies have shown an association between markers of 
inflammation, most notably proinflammatory cytokines, and PNS (Cleeland et al 2003, Fumaz et 
al 2012). However, investigators have not attained a clear consensus regarding the etiological role, 
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if any, of cytokines in chemotherapy-related PNS (Dantzer et al 2001, Cleeland et al 2003, Lee et 
al 2004). More recently, conjectures about the biological basis underlying the development and 
persistence of chemotherapy-related PNS have shifted to include mechanisms that would account 
for both the short-term presentation of symptoms, as well alterations that could be biologically 
“remembered” or retained for months/years.  One potential means whereby chemotherapy could 
induce the development and persistence of PNS is if that therapy resulted in the acquisition of 
somatic chromosomal instability.  This soma-wide instability could result in the development of a 
clonal population(s) of cells having a chromosomal imbalance, which, in turn, could lead to the 
development of PNS and/or other health conditions. Recent advances in methodology support the 
premise that somatic mosaicism and/or mutations are associated with a variety of health conditions 
(Grayson, et al., 2010; Forsberg, et al,  2013; Poduri, et al., 2013; Li, et al., 2014). In particular, 
spontaneous somatic chromosomal instability/mosaicism has been associated with the 
development of cancer (Santos et al . 2009, Cardinale et al ,  2012, Chang et al. 2010);  dyskeratosis 
congenital (Jongmans, et al., 2012); rheumatoid arthritis (Tascioglu et al., 2005); and osteoarthritis 
(Castellanos et al. 2004, Dahlen et al., 2001, Kinne et al., 2001, Mertens et al., 1996, Broberg et 
al., 1998). Somatic chromosomal mosaicism has also been associated with several conditions 
involving behavior and/or cognition, including but not limited to, Alzheimer’s disease 
(Zekanowski and Wojda 2009; Yurov, et al., 2013), Parkinson disease (Migliore et al 2001), age-
related cognitive decline (Faggioli, et al., 2011), schizophrenia (Yurov, et al., 2013; Ruderfer, et 
al., 2013), and stressful events (York, et al., 2013).  
  
      Chromosomal instability has been observed by several investigators in cells from breast cancer 
tumors (Yoon et al 2003, A’Hern et al 2013, Burell et al 2010 , Kabalar et al 2012, Niu et al 2013, 
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Ottesen et al 2003, Jiang et al 2014), as well as in cells from peripheral tissues (typically blood) of 
people diagnosed with cancer prior to their receipt of treatment (Santos et al 2010, Milosevic-
Djordjevic et al 2010, Harsimran et al 2009).  While few in number, studies have also been 
completed to evaluate the frequency of chromosomal instability in peripheral blood following 
exposure to various treatments for breast cancer, with these reports noting an increase in 
chromosomal instability values soon after radiation treatment (Jagetia et al 2001; Gamulin et al 
2010; Vral et al 2011; Cardinale et al 2012) or radiation and chemotherapy (Aristei et al 2009; 
Milosevic-Djordjevic et al 2011).   
     Given that chromosomal instability appears likely to arise after treatment for breast cancer, it 
follows that these chromosomal aberrations might result in somatic mosaicism that could 
compromise the function of the cells containing these aberrations. Based on this premise, we 
hypothesized that an increase in micronuclei frequencies arises following chemotherapy and that 
this increase in somatic chromosomal instability is associated with the development and/or 
persistence of PNS in women receiving therapy for breast cancer.  To test this hypothesis we 
designed a 2-year longitudinal study to determine the frequency and retention of acquired 
chromosomal changes in women diagnosed and treated for breast cancer. This current study 
reports the findings from one year of follow-up for this longitudinal study.  The time points 
evaluated include: baseline (before the initiation of chemotherapy); mid-cycle (typically at the 4th 
chemotherapy treatment); 6 months following the initiation of chemotherapy (at which time a 
subset of women have recently received radiation therapy); and 1 year following the initiation of 
chemotherapy.  
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Materials & Methods 
 
Study Participant Ascertainment and Specimen Collection  
     A total of 76 women with early stage (I to IIIA) breast cancer, who ranged in age from 23 to 
71 years old, were ascertained through 5 regional cancer centers in Central Virginia. To identify 
potential study participants, a member of the research team attended the weekly interdisciplinary 
Breast Health meetings that were held at the Virginia Commonwealth University Medical Center 
(VCUMC).  Study eligibility criteria for participants were: (1) 21 years or older;  (2) diagnosis of 
early stage breast cancer with a scheduled visit to receive chemotherapy; and (3) female (males 
were excluded since too few male participants were available for study).  Exclusion criteria 
included: (1) a history of previous cancer, or chemotherapy; (2) a diagnosis of dementia;  (3) active 
psychosis; or (4) a history of immune-related diagnoses (e. g. multiple sclerosis; systemic lupus 
erythematosus).  After providing informed consent (VCU IRB #HM 13194), participants were 
enrolled and the first study visit was scheduled prior to the initiation of chemotherapy. Study visits 
took approximately one hour to complete. A peripheral blood sample was collected at each of the 
4 time points by venipuncture or through an existing access device and transported (same day) to 
our (Jackson-Cook) cytogenetics laboratory. The specimens were coded prior to their delivery to 
the lab to ensure that the cytogeneticists were unaware of the clinical history and PNS status of 
each participant at the time of sample processing and evaluation. 
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Demographic, Lifestyle, Breast Tumor and Other Health Information 
 
     Demographic information for the study participants was collected by self-report using a 
questionnaire format. Demographic variables evaluated in this current report included age, race, 
and income. Similarly, lifestyle factors [nutritional practices (eating vegetables/fruit); smoking 
status, and ethanol usage] and health attributes not directly related to the diagnosis of breast cancer 
[menopausal status (pre- or post-)] that were evaluated in this 1 year follow-up report were 
obtained from self-report. Medical records were used to determine body mass index, breast tumor 
attributes, and chemotherapy regimens. Based on the tumor fluorescent in situ hybridization 
(FISH) and/or immunohistochemical testing results, which were obtained from the medical 
records, the tumors were categorized as luminal A (human epidermal growth factor receptor 2 
[HER2] -; estrogen receptor and/or progesterone receptor +), luminal B (HER2+; estrogen receptor 
and/or progesterone receptor +), HER2 positive (HER2+; estrogen receptor -; progesterone 
receptor -), or triple negative (HER2-; estrogen receptor - ; progesterone receptor -) (Perou, et al., 
2000; Hu, et al., 2006,  Fan, et al., 2006; Voduc, et al., 2010; Carey, et al., 2013).   
 
Chemotherapy and Radiation Treatments 
     The chemotherapy treatments received for study participants were determined by medical 
record review. Three primary types of chemotherapy administered included: (1) taxotere 
(docetaxel), adriamycin (doxorubicin), and cyclophsophamide [TAC]; (2) taxotere and 
cyclophosphamide [TC]; or (3) taxotere (docetaxel), carboplatin (paraplatin); and herceptin 
(transtuzumab) [TCH]. The recognition of each participants’ receipt of radiation therapy (or lack 
thereof) was also derived from reviews of the medical records. All blood specimens were collected 
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within 1 month after treatment, with most chemotherapy specimens being collected within 2 weeks 
of exposure.  
 
 
Chromosome Instability Methodology 
      Chromosomal instability levels were quantified for each specimen using the cytokinesis-block 
micronucleus (CBMN) and cytome assay (Fenech, 2006). A micronucleus (micronuclei) (MN) is 
(are) small chromatin containing structure(s) juxtaposed to a parent nucleus (Figure 3). The CBMN 
assay was selected for the chromosomal instability assessments because it allows for: (1) the 
quantification of both numerical and structural cytogenetic findings; (2) the analysis of a large 
number of cells, thereby enhancing one’s ability to detect even low levels of instability; and (3) 
minimization of in vitro growth selection  (only 1 round of cell division is completed in vitro) and 
minimization of technical artifacts due to processing (for example, the CBMN assay does not show 
chromosome “loss” due to cell breakage at harvesting or slide making, which can occur when 
assessing metaphase chromosomes).  
     
      Leukocytes, which were isolated using Histopaque-1077 (Sigma), were established in culture 
according to the protocol of Fenech (1993).  Briefly, following their mitogenic stimulation using 
phytohemaglutinin (PHA), lymphocytes were arrested at cytokinesis by adding cytochalasin B to 
the cells 44 hr after their culture initiation. The cells were harvested 72 hours after culture initiation 
and slides prepared (2 per specimen) as described previously (Leach and Jackson-Cook, 2001) 
(Figure 4) 
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 Micronuclei, buds, and/or bridges were visualized following giemsa staining (4% Harleco 
Giemsa solution) and identified according to the criteria established by Fenech (2006).  The 
proportion of abnormalities was calculated by adding the values obtained from the two replicate 
scores (1000 binucleates were evaluated from each of two slides for a total of 2000 binucleates per 
study participant). The total number of binucleates with abnormalities was then divided by the 
total number of  binucleates scored.  
  
 
PNS Assessment  
     PNS were assessed based on study participant self-reporting or computer interfaced 
performance measures using well established biobehavioral tools. Briefly, cognitive dysfunction 
was evaluated using the CNS Vital Signs (CNSVS, https://www.cnsvs.com) computerized 
neurocognitive testing system, in which practice effects are minimized by randomly generated 
alternate test forms or random selections from item banks (ref). Cognitive measures evaluated in 
this study included the overall cognitive index, memory, complex attention, psychomotor speed 
and cognitive flexibility domains.  Depressive symptoms and anxiety were identified using the 
hospital anxiety and depression scale (HADS), which is a brief (14-item) self-report questionnaire 
that has well-established reliability and validity for both depressive symptoms and anxiety in 
women with breast cancer. Fatigue symptoms were evaluated using the Brief Fatigue Inventory 
(BFI), which is a clinically validated tool used to assess cancer-related fatigue and its impact on 
daily functioning. Participant sleep disturbances were assessed through self-report using the 21-
item General Sleep Disturbance Scale (GSDS), which evaluates various aspects of sleep 
disturbance (quality and quantity of sleep, sleep onset latency, number of awakenings, excessive 
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daytime sleepiness, and medication use) over the past week. Pain was evaluated using the Brief 
Pain Inventory (BPI), which assesses the severity and location of pain, pain medication use, 
amount of pain relief in the past 24 hours or the past week, and the impact of pain on daily 
functions. The arithmetic mean of the 4 severity items were used as a measure of pain severity, 
and the arithmetic mean of the 7 interference items were used as a measure of pain interference. 
Perceived stress was measured using the 10-item Perceived Stress Scale (PSS). 
 
 
Statistical analysis 
Descriptive statistics of MN/cytome frequencies were computed for the demographic, 
tumor characteristic, treatments, and PNS symptoms variables noted above. All data were 
examined graphically to determine their distributional properties. It was anticipated that the 
MN/cytome frequencies would follow a log-normal distribution as is typical with MN frequency 
data (Ceppi, et al., 2011).   However, because of the relatively high number of MN in this 
population, the MN frequencies were approximately normally distributed.    
 
Using the model building approach proposed by Hosmer and Lemeshow (2000), a mixed 
effects linear model (Brown and Prescott, 2006) was fit (by R. K. Elswick, Jr.) to determine the 
best subset of predictors of MN/cytome frequencies.  In the first stage of the model building 
process, a base model was selected that represented the design of the data collection and of the 
timing of the treatments (chemotherapy and radiation). Fixed effects included time (baseline, mid-
chemo, six months and 1 year post-chemo), chemotherapy (TAC, TC and TCH), time by 
chemotherapy interaction (chemotherapy was administered only during time point 2), radiation 
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(Yes/No);  time by radiation interaction (radiation was only administered at time point 3), and a 
random effect for study participant. In the second stage, each potential predictor was fit 
individually with the base model and, if the p-value was 0.25 or less, that predictor was used in 
the next stage. Potential predictors included demographic variables (age, race, BMI, income, 
menopausal status, current smoking status & alcohol consumption, and lifestyle nutrition), tumor 
characteristic variables (grade, stage. luminal A, luminal B, triple negative & HER 2 positive 
status), surgery, PNS  variables (HADS depression, HADS anxiety, BPI worst, BPI least, BPI 
average, BPI now, BPI relief, BPI interference, BFI total, BFI now, BFI usual, BFI worst, BFI 
interference, GSDS total, total PSS) and cognition variables (NCI, Memory, Complex attention, 
Psychomotor speed & Cognitive flexibility). In the third stage, all potential regressors (p< 0.025) 
were put into a multiple variable model. This initial model was further refined by sequentially 
removing variables from the model with the highest p-values (backward stepwise) until all 
remaining factors had a p-value of 0.05 or less. At this stage, all pairwise interactions were added. 
Again using a backward stepwise approach, all interaction terms with p-values less than 0.05 were 
removed. This model was considered the final prediction model. The SAS v9.2 and JMP v11.1 
statistical packages were used for these analyses (SAS 9.3 and JMP 11.1: SAS Institute Inc., SAS 
Campus Drive, Cary, North Carolina 27513.). In order to limit type I errors, an alpha level of 
p<0.05 was used for all statistical tests. 
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Figure 3: The appearance of a micronucleus (MN) juxtaposed to a binucleated   
lymphocyte stained by Giemsa. 
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Figure 4: Description of the Cytokinesis Block MN (CBMN) assay. Briefly, the buffy caot 
consisting of leukocytes was isolated using Histopaque. Following their mitogenic stimulation 
using phytohemaglutinin (PHA), Lymphocytes were arrested at cytokinesis by adding 
cytochalasin B to the cells 44 hr after their culture initiation. The cells were harvested 72 hours 
after culture initiation and slides were prepared (2 per specimen), stained and scored. 
 
 
 
 
 
 
 
 
 
 
Acquired epigenetic/chromosomal changes in women with breast 
cancer are associated with chemotherapy and the acquisition/
persistence of psychoneurological symptoms. 
Conclusions 
Background, Hypothesis and Aims 
Molecular Cytogenetics Laboratory 
Department of Pathology 
What are the factors that associate with MNF ?  
Did leukocyte methylation patterns change with 
chemotherapy? 
Supported by NIH grant R01 NR012667 (D Lyon and C Jackson-Cook, PIs). 
Figure from Illumina 
Website 
(B) 
 
• The study showed 6 predictors of MNF: Visit, type of tumor, chemotherapy, radiation, race, 
& stress. 
• Micronuclei frequencies in women diagnosed with breast cancer increased after exposure 
to chemotherapy and radiation. Also, differences were observed based on the type of 
chemotherapy  received (AC higher than TC or TCH). 
• Decreases in MNF were observed after 1 year following treatment, but did not return to 
baseline levels. 
• White women had overall higher MNF as compared to African American women. 
• Women with more stress had higher MNF. 
• Methylation alterations were acquired in response to chemotherapy, with hypomethylation 
changes being seen most often; especially following AC. Changes were observed for 
multiple types of sequences for both AC and TC and were predominantly associated with 
RNA transcripts. 
 
 
Continuation of these studies may allow for the recognition of consistently acquired genomic/epigenomic 
alterations that contribute to the development and/or persistence of PNS in women treated for breast cancer. This 
knowledge could be used to identify  biomarkers for predicting a woman s risk for developing PNS, thereby 
empowering her to make informed decisions regarding treatment options. These studies may also provide the 
foundational basis for the development of targeted interventions to possibly alleviate or reverse the PNS 
associated with breast cancer and its chemotherapy.   
Women with HER2+ expression/treatment showed lower MNF. A significant increase in MNF 
was observed in the women following chemotherapy (V2) and following radiation (V3). A 
significant difference in MNF was also observed between chemotherapy regimens at V2:  AC > 
TC or TCH. 
(A) Variation in changes in methylation patterns were noted among patients. (B) Acquired 
hypomethylation was seen more often in women receiving AC vs TC.  (C) A trend toward more 
hypomethylation alterations involving CpG islands was observed with AC.  For both chemo 
types the majority of changes occurred in open sea  sequences, followed by CpG shores and 
islands. (D) The majority of both AC & TC hyper- and hypomethylation changes occurred in RNA 
coding sequences. Using a FDR of 1%, 15,939 differentially methylated regions (3.4% of total 
array sites) were observed at mid-chemo compared to baseline time points. Specific genes that 
were noted to show altered patterns included (but were not limited to) those involved in DNA 
repair, transcription regulation, signal transduction pathways, and neuronal regeneration. 
    Treatment advances have resulted in improvements in survival for women diagnosed with 
breast cancer, but many of these survivors report acquiring persistent adverse side effects 
following treatment. These psychoneurological symptoms (PNS) include cognitive 
dysfunction, depression, anxiety, fatigue, sleep disturbances, and pain. The etiology of these 
PNS is not fully known. We offer the hypothesis that inflammatory activation is an early step 
in a cascade of biological changes leading to genomic and/or epigenetic alterations that 
contribute to PNS. Alternatively, epigenetic alterations may occur first, leading to 
inflammatory activation. These epigenetic changes could also lead to chromosomal 
instability. Each of these genomic/epigenetic factors, acting either singly or in concert, could 
contribute to the development/ persistence of PNS since they would provide a means for 
remembering  the biological effects after chemotherapy and have plasticity to explain 
responsiveness to environmental exposures (as well as G x E interactions). They also have 
the potential for reversibility, with the latter attribute being important for the potential 
development of therapeutic interventions.  
(A) (C) Types of sequences with baseline to mid-chemo 
methylation alterations*  
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(B)  Total methylation 
changes* 
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MNF increase significantly following the initiation 
 of treatments as compared to baseline levels.  
              Factors predictive of MNF: 
1. Visit (p<.0001): MNF increase with treatment 
2. Chemotherapy (p=.0213): MNF highest in AC treated 
patients 
3. HER2+ (all received trastuzumab)(p=0.0012): MNF 
lower    
4. Radiation (p=.0185): Subset of women treated 
5. Race (p=.0129): C women had higher MNF than AA 
6. Stress (p=.0044): Women with more stress had higher 
MNF 
Goal, Study Design, Aims,  and Methods 
Specific Aims: 
The primary aims of this study were to 
collect blood specimens from women 
having a diagnosis of breast cancer 
and  longitudinally determine: 
1. The frequency of acquired 
chromosomal instability and genome-
wide epigenetic changes present at 
baseline and following treatments. 
2. The relationship between acquired 
chromosomal and/or epigenetic 
alterations and the development/
persistence of PNS. 
Investigate the biological basis for the development of  PNS associated with 
chemotherapy, or the cancer itself, in women treated for BC. 
Goal : 
Longitudinal+Study+Design:+(5+4me+points) 
(A) 
Methods: 
Aboalela N1, Lyon D2,, Elswick R2, York TP 1, Kelly DL2, Jackson-Cook C1,3 
1Department of Human and Molecular Genetics, 2School of Nursing,  3Department of Pathology, Virginia 
Commonwealth University, Richmond, VA 
! ! ! ! ! ! ! ! ! ! !
! ! !
Demographic,
,
A,American,, N=22, !! Caucasian, N=51, !!
! ! !
Measure, TAC! TC! TCH! TAC! TC! TCH! Total!
! ! !
!! (n=10),! (n=6)! (n=6)! (n=30)! (n=16)! (n=5)! (n=73)!
! ! !
Income, !! !! !! !! !! !! !!
! ! !
Less!than!30,000! 5!(22.73)*! 4!!(18.18)!!! 3!(13.64)! 6!!(11.76)! 1!!!(1.96)! 0! 19!!!!!(26.03)!
! ! !
30,000?59,999! 3!(13.64)! 2!!(9.01)! 3!(13.64)! 6!!(11.76)! 1!!!(1.96)! 0! 15!!!!!(20.55)!
! ! !
60,000?89,999! 1!!!!(4.55)! 0! 0! 7!!(13.73)! 8!(15.69)! 3!!!(5.88)! 19!!!!!(26.03)!
! ! !
90,000+! 1!!!!(4.55)! 0! 0! 11(21.57)! 6!(11.76)! 2!!!(3.92)! 20!!!!!(27.40)!
! ! !
Current,Smoking,
Status, ! ! ! ! !
!
!!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Yes! 2!!!(9.01)! 3!!(13.64)! 2!!(9.01)! 5!!!(6.94)! 2!(2.77)! 1!!!(1.39)! 15!!!!(20.83)!
! ! !
No! 8!(36.36)! 3!!(13.64)! 4!(18.18)! 25(34.72)! 13!(18.06)! 4!!!(5.56)! 57!!!!(79.17)!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Current,Ethanol,
Consumption, ! ! ! ! ! ! !!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Yes!
3!(13.64)! 1!!!(4.55)! 2!!!(9.01)! 19(37.25)! 12!(23.53)! 4!!!!(7.84)! 41!!!(56.16)!
! ! !
No! 7!(31.82)! 5!!(22.73)! 4!(18.18)! 11(21.57)! 4!!!!!(7.84)! 1!!!!(1.96)! 32!!!!(43.84)!
!
* Number (%) 
!
!
!
!
!
! !
!
!
! !
!
!
!
!
!
!
! !
!
!
! !
!
!
!
!
!
!
! !
!
!
! !
!
!
!
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Results 
 
     A total of 73 of the 76 women initially recruited for this longitudinal study elected to complete 
the first year of sample collections (96% retention rate), with 1 participant providing only a 
baseline specimen (withdrew due to lack of time/interest); and 2 participants failing to provide 
specimens for all 4 times (both women cited lack of time as their reason for not continuing). For 
times 3 and 4, assessments were completed for 67 and 50 of the study participants, respectively, 
with the smaller number of specimens evaluated for these times reflecting pending specimen 
collections in this ongoing, 2-year longitudinal study. The majority of the women in this study 
received a TAC chemotherapy regimen (n=39), followed by TC treatment (n=21), or TCH 
treatment (n=11). Two of the women received a cyclophosphamide, methotrexate and 5 
fluorouracil treatment (CMF). Given the small number of women receiving this treatment, this 
group was excluded from the analysis. Thus, comparisons of factors influencing chromosomal 
instability frequencies were completed for a total of 71 women. 
 
      Demographic data, tumor characteristics, and treatment information is/are shown for the 71 
women fully participating in this longitudinal study in Tables 8-10.  These participants included 
22 women of African American heritage and 49 women of Caucasian heritage.  Only 2 women (1 
in the African American cohort and 1 in the Caucasian cohort) self-reported that they were of 
Hispanic ethnicity. Thus, given the small number of women having a Hispanic heritage, this sub-
group was not analyzed separately.  Since none of the 14 women who reported smoking met the 
criteria of a heavy smoker, as suggested by Fenech et al. (2006) for assessments of the influences 
of smoking on micronuclei frequencies, smoking habits were not included in our statistical model.  
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     The average age of the study participants was 51.59 years, with a significant difference in age 
being observed between the African American (mean= 47 years, s.e.=1.89 years) and Caucasian 
(mean= 53 years, s. e. =1.46 years) sub-groups (p=0.006) (Table 8). Annualized income levels also 
varied between the racial groups, with the Caucasian patients having significantly higher incomes 
than the African American women (p<0.0001). As expected, the majority of women (56%) were 
post-menopausal with 44% being either pre- or peri-menopausal (Table 8).  No significant 
difference in menopausal status was detected between the African American and Caucasian study 
participants.  However, significantly more Caucasian women reported consuming alcohol (69%) 
than African American women (27%) (p=0.0016 ) (Table 8).    
 
     Due to the inclusion criteria established for this study, all of the study participants had early 
stage breast cancer (stages I to IIIA). The participants’ clinical pathological characteristics and 
their pre-chemotherapy treatments are summarized in Tables 9 and 10, respectively. While the 
proportion of African American women having grade 3 (Grade 3 - 40.91%) tumors tended to be 
lower than the proportion of Caucasian women (Grade 3 – 59.18%) these tumor distributions were 
not significantly different (p=0.153). Similarly, while no significant difference in the proportion 
of the 4 intrinsic subtypes of tumors was observed between the racial sub-groups (p=0.107), there 
was a trend toward a higher proportion of triple negative tumors and a lower proportion of luminal 
A tumors in the African American women (triple negative tumors-36.36%; luminal A tumors-
36.36%) compared to the Caucasian women (triple negative tumors-24.49%; luminal A tumors-
61.22%) (Table 9).  As expected, due to the lack of a significant difference in the tumor 
characteristics in the African American compared to Caucasian women, no significant differences 
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were observed in the treatment regimens between the racial groups (chemotherapy p=0.2011; 
radiation p=0.213).  
 
     To determine if any of the treatment, health, demographic, or symptom variables were 
associated with MN/cytome abnormality frequencies, the data were fit to a mixed effects linear 
model (Table 11). The final optimized model identified 8 variables that had a significant predictive 
association with MN/cytome abnormality frequencies (Table 11). These variables included: (1) 
the time point at which the specimen was collected (p<0.0001); (2) the type of chemotherapy 
treatment (p=0.0463); (3) exposure to radiotherapy (p=0.0004); (4) race (p=0.0037); (5) having a 
luminal B tumor categorization (p=0.0182); (6) having a triple negative tumor categorization 
(p=0.0446); (7) total perceived stress (p=0.0123); and (8) cognitive flexibility domains 
(p=0.0238).  
 
     The strongest significant association between MN/cytome abnormality frequencies was the 
time at which the specimens were collected (p<0.0001) (Table 11 & Figure 5).  Almost all women 
showed a significant increase in their chromosomal instability frequencies at time point 2 (the mid-
chemo specimen). Those participants who received radiation showed an additional increase in their 
MN/cytome abnormality frequencies at time point 3 (figure 6). Interesting, while the chromosomal 
instability frequencies were highest at times 2 and 3, the time 4 values (1 year following the 
initiation of chemotherapy) tended to remain higher than baseline values  (Table 11).  
 
      The frequency of MN/cytome abnormalities also differed based on the type of treatment the 
participants received.  The greatest increase in MN/cytome abnormality frequencies in response to 
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the administration of chemotherapy (time point 2) was observed for the women who received TAC 
treatment (Figure 5). However, the women who received TCH treatment had the highest overall 
value of chromosomal instability (mean = .071, SE = .0042) when compared to women receiving 
TAC (mean=.063 SE =.0043) or TC (mean=058 ; SE = .0048 ) chemotherapy regimens (p=0.0463) 
(Table 4 & Figure 2). Moreover, the subset of women who received radiation had significantly 
higher MNF (mean=.073; SE=.0033) than women who didn’t receive radiation (mean=.057; 
SE=.0042) (Figure 6 & Table  11).  
 
 
Race was also observed to be predictive of chromosomal instability frequencies (p=0.0037), with 
values being significantly lower in the African American participants (mean=.059; SE= .0043) 
compared to the Caucasian participants (mean=.071; SE= .0031). One might conjecture that this 
association between acquired chromosomal instability and race is confounded by other influences 
(e. g. age differences between the racial sub-groups). However, the consistent recognition of an 
association between MN/cytome abnormality frequencies and race following the stepwise removal 
of other potential confounding variables (including age and tumor characteristics) suggests that 
there may be a separate, differential impact of race on chromosomal instability frequencies 
following treatment for breast cancer (Table 11).  
 
     Tumor characteristics were also observed to be predictive of MN/cytome abnormality 
frequencies with luminal B tumors being associated with lower overall chromosomal instability 
values (mean=.057; SE=.0060), as compared to other types ( mean=.073; SE=.0024) (p=.0182). 
Conversely, triple negative tumors were associated with higher values (mean=.0693; SE=.0043) 
as compared to other tumors (mean=.0611; SE=.0031) (p= .0446) (Table 11). Given that the tumor 
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characteristics determine the type of therapy regimen received by the study subjects, it is feasible 
that this association is confounded by the impact of chemotherapy and/or radiation. However, as 
noted previously in regard to race, the retention of consistent significant association values 
between these tumor characteristic variables and MN/cytome abnormality frequencies following 
the stepwise removal of the potentially related therapy variables suggest the presence of a separate 
effect (above that related to therapies) for the tumor sub-types on peripheral blood MN/cytome 
abnormality frequencies. 
     
    The best fit model also showed that the participants’ total perceived stress levels were predictive 
of chromosomal instability frequencies (p=0.0123), with women reporting higher stress levels also 
having higher values of instability. A second symptom associated with MN/cytome abnormality 
frequencies was cognitive flexibility, with a significant positive relationship being observed 
(higher instability values in women with higher cognitive flexibility domains)(p=.024). Although 
complex attention measures were also initially suggestive of an association with MN/cytome 
abnormality frequencies (Table 11), this variable did not yield a significant difference in the 
reduced model.  No other PNS evaluated showed significant associations with acquired 
lymphocyte chromosomal instability frequencies.    
 
 
 
 
 
 
 
50 
 
     Other variables that were tested and found to show no significant association with micronuclei 
frequencies in the initial or final models were age, alcohol consumption, income, nutritional habits, 
body mass index, menopausal state, tumor grade, tumor stage, luminal A and HER2+ tumor sub-
groups, types of surgery, depressive symptoms, anxiety, pain measures, fatigue measures, 
memory, psychomotor speed, and overall cognitive function.  
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Table 8. Demographic, health and lifestyle findings in study participants receiving 
 chemotherapy for breast cancer 
 
 
 
Demographic 
Variable 
African American  
n=22 (100) 
Caucasian 
n=49 (100) 
 
TAC TC TCH TAC TC TCH Total 
n=10  
(45.451) 
n=6 
(27.27) 
n=6 
(27.27) 
n=29 
(59.18) 
n=15 
(30.61) 
n=5 
(10.20) 
n=71 
(100) 
Income 
Less than 
30,000 
5 
(22.73) 
4     
(18.18) 
3 
(13.64) 
6     
(12.24) 
1 
(2.04) 
0 19 
(26.76) 
30,000-59,999 3 
(13.64) 
2     
(9.09) 
3 
(13.64) 
6      
(12.24) 
1 
(2.04) 
0 15 
(21.13) 
60,000-89,999 1 
(4.55) 
0 0 6    
(12.24) 
7 
(14.29) 
3 
(6.12) 
17 
(23.94) 
90,000+ 1 
(4.55) 
0 0 11   
(22.45) 
6 
(12.24) 
2 
(4.08) 
20 
(28.17) 
 
Age 44.00,  
3.402 
47.00, 
2.52 
50.50,  
2.93 
52.17, 
1.73 
57.13, 
2.64 
50.20, 
6.35 
 
 
Menstrual Status 
Pre- or Peri- 7 
(31.82) 
3    
(13.64) 
2 
(9.09) 
11   
(22.45) 
5 
(10.20) 
3 
(6.12) 
31 
(43.66) 
Post- 3 
(13.64) 
3    
(13.64) 
4 
(18.18) 
18    
(36.73) 
10 
(20.41) 
2 
(4.08) 
40 
(56.34) 
 
BMI 31.99, 
2.682 
29.84, 
2.54 
35.56, 
6.26 
30.09, 
1.47 
26.77, 
0.88 
37.28, 
4.70 
 
 
Nutrition3 
 
2.59, 
0.182 
2.22, 
0.21 
2.35, 
0.25 
2.72, 
0.11 
2.92, 
0.13 
2.67, 
0.30 
 
 
Current Smoking Status 
Yes  2 
(9.09) 
3     
(13.64) 
2 
(9.09) 
4 
(8.16) 
2 
(4.08) 
1 
(2.04) 
14 
(19.72) 
No 8 
(36.36) 
3     
(13.64) 
4 
(18.18) 
25 
(51.02) 
13 
(26.53) 
4 
(8.16) 
57 
(80.28) 
 
Current Ethanol Consumption 
Yes 3 
(13.64) 
1  
(4.55) 
2 
(9.09) 
19    
(38.78) 
11 
(22.45) 
4      
(8.16) 
40 
(56.34) 
No 7 
(31.82) 
5     
(22.73) 
4 
(18.18) 
10   
(20.41) 
4 
(8.16) 
1 
(2.04) 
31 
(43.66) 
1Number in parenthesis is the percentage of study participants for the category (%) 
2Mean, standard error 
3Nutritional assessments for the participants’ intake of fruits and vegetables 
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Table 9. Study participants’ breast tumor characteristics  
 
 
 
Tumor 
Characteristic 
African American 
N=22 (100*) 
Caucasian 
N=51 (100*) 
  
TAC TC TCH TAC TC TCH Total 
(n=10) 
(45.45*) 
(n=6) 
(27.27) 
(n=6) 
(27.27) 
(n=29) 
(59.18) 
(n=15) 
(30.61) 
(n=5) 
(10.20) 
(n=71) 
(100) 
Luminal A 
Yes 6 
(27.27) 
2 
(9.09) 
0 21   
(42.86) 
9   
(18.37) 
0 38 
(53.52) 
No 4 
(18.18) 
4 
(18.18) 
6 
(27.27) 
8 
(16.33) 
6 
(12.24) 
5 
(10.20) 
33  
(46.48) 
Luminal B  
Yes 0 0 2 
(9.09) 
2     
(4.08) 
0 3     
 (6.12) 
7    
(9.86) 
No 10 
(45.45) 
6 
(27.27) 
4 
(18.18) 
27 
(55.10) 
15    
(30.61) 
2 
(4.08) 
64  
(90.14) 
Triple negative 
Yes 3 
(13.64) 
4 
(18.18) 
1 
(4.55) 
6    
(12.24) 
6 
(12.24) 
0 20 
(28.17) 
No 7 
(31.82) 
2 
(9.09) 
5 
(22.73) 
23  
(46.94) 
9   
(18.37) 
5      
(10.20) 
51   
(71.83) 
HER2+,ER-,PR- 
Yes 1 
(4.55) 
0 3 
(13.64) 
0 0 2 
(4.08) 
6 
(8.45) 
No 9 
(40.91) 
6 
(27.27) 
3 
(13.64) 
29 
(59.18) 
15 
(30.61) 
3 
(6.12) 
65 
(9.15) 
Grade 
1 1 
(4.55) 
0 0 2     
(4.08) 
2 
(4.08) 
0 5     
(7.04) 
2 5 
(22.73) 
3 
(13.64) 
4 
(18.18) 
12   
(24.49) 
4 
(8.16) 
0 28   
(39.44) 
3 4 
(18.18) 
3 
(13.64) 
2 
(9.09) 
15    
(30.61) 
9   
(18.37) 
5 
(10.20) 
38   
(53.52) 
Stage 
I 1 
(4.55) 
4 
(18.18) 
0 5    
(10.20) 
8 
(16.33) 
2 
(4.08) 
20   
(28.17) 
IIA 6 
(27.27) 
2 
(9.01) 
3 
(13.64) 
10   
(20.41) 
6 
(12.24) 
1 
(2.04) 
28   
(39.44) 
IIB 3 
(13.64) 
0 3 
(13.64) 
6    
(12.24) 
1 
(2.04) 
2 
(4.08) 
15  
(21.13) 
IIIA 0 0 0 8    
(16.33) 
0 0 8    
(11.27) 
* Number (%) of participants. 
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Table 10. Study participant treatments 
 
 
 
 
Treatment 
African American 
N=22 (100*) 
Caucasian 
N=51 (100*) 
 
TAC TC TCH TAC TC TCH Total 
(n=10) 
(45.45*) 
(n=6) 
(27.27) 
(n=6) 
(27.27) 
(n=29) 
(59.18) 
(n=15) 
(30.61) 
(n=5) 
(10.20) 
(n=71) 
(100) 
Surgery 
Biopsy 3 
(13.64) 
0 0 2   
 (4.08) 
0 0 5     
(7.04) 
Lumpectomy 4 
(18.18) 
0 1 
(4.55) 
8     
(16.33) 
6 
(12.24) 
1 
(2.04) 
20   
(28.17) 
Segmental 1 
(4.55) 
5 
(22.73) 
3 
(13.64) 
1     
(2.04) 
6 
(12.24) 
0 16   
(22.54) 
Simple 2 
(9.01) 
1 
(4.55) 
2 
(9.01) 
18   
(36.73) 
3 
(6.12) 
4 
(8.16) 
30   
(42.25) 
Neoadjuvant 
Yes 3 
(13.64) 
0 1 
(4.55) 
2    
 (4.08) 
1 
(2.04) 
0 7     
(9.86) 
No 7 
(31.82) 
6 
(27.27) 
5 
(22.73) 
27   
(55.10) 
14 
(28.57) 
5 
(10.20) 
64   
(90.14) 
Radiation 
Yes 9 
(40.91) 
5 
(22.73) 
5 
(22.73) 
23   
(46.94) 
12 
(24.49) 
1     
(2.04) 
55    
(77.46) 
No 1 
(4.55) 
1 
(4.55) 
1 
(4.55) 
6     
(12.24) 
3 
(6.12) 
4     
(8.16) 
16    
(22.54) 
 
* Number (%) of participants.  
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Table 11. Mixed Effects Linear Model Fitting Assessment of Predictive Associations  
of Variables with Micronuclei/Cytome Abnormality Frequencies. 
 Base Model1 Final model2 
 
Variable 
 
p value 
Least Squares 
Mean 
Std. 
Error 
 
p value 
Visit 
1 
2 
3 
4 
  
0.050 
0.067 
0.075 
0.069 
 
0.0044 
0.0042 
0.0043 
0.0045 
<0.0001 
 
Age 0.973    
Race 
African American 
Caucasian 
  
0.059 
0.071 
 
0.0043 
0.0031 
0.0037 
Chemotherapy 
TAC 
TC 
TCH 
 
 
 
0.063 
0.058 
0.071 
 
0.0043 
0.0048 
0.0042 
0.0463 
Radiation 
Yes 
No 
  
0.073 
0.057 
 
0.0033 
0.0042 
0.0004 
Radiation by visit    0.0077 
BMI 0.437    
Income 0.373    
Menopausal status 0.507    
Alcohol consumption 0.078    
Tumor grade 0.805    
Tumor stage 0.234    
Luminal A tumors 0.926    
Luminal B tumors 
Yes 
No 
  
0.057 
0.073 
 
0.0060 
0.0024 
0.0182 
Triple negative tumors 
Yes  
No 
  
0.0693 
0.0611 
 
0.0043 
0.0031 
0.0446 
HER2 + 0.640    
Surgery 0.262    
HADS  depressive symptoms 0.814    
HADS  anxiety 0.104    
BPI Measures  
Worst pain 
 
0.329 
   
Least pain 0.293    
Average pain 0.166    
Current pain 0.416    
Pain relief 0.598    
Pain interference 0.236    
BFI Measures 
Total fatigue 
 
0.188 
   
Current fatigue 0.664    
Usual fatigue 0.100    
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Worst fatigue 0.171    
Fatigue interference 0.1571    
 
Perceived Stress 
 
 
   
0.0123 
Nutrition (fruits and vegs) 0.323    
Cognitive Measures 
NCI 
 
0.495 
   
Memory 0.991    
Complex attention 0.013    
Psychomotor speed 0.318    
Cognitive Flexibility    0.0238 
1The base model, which was determined by the study design, was:  
 
MN frequency=Visit + Chemotherapy (3 types) + Radiation therapy + Visit by Chemotherapy* + 
Visit by Radiation therapy* with the study subject being a random effect   
 
*The visit by chemo and visit by radiation interaction variables allowed these values to differ across time points. 
 
2The final model reflects the variables that remained significantly associated with MN frequencies after 
stepwise removals. 
  
 
 
56 
 
 
 
 
 
Figure 5: The effect of different types of chemotherapy on MN proportions. 
Women treated with TCH (mean=0.071) showed the overall highest MNF followed by TAC 
(mean=0.063) then TC (mean=0.058) (p=0.04). However, at visit 2 (during the administration of 
chemotherapy), patients treated with TAC had the highest level of acquired changes in MNF 
followed by TC, then TCH.  
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 Figure 6: The effect of radiotherapy on MN proportions. 
MNF in women treated with radiation were not significantly different from those of women who 
were not treated with radiation at visit 1 or 2 (before the administration of radiation). However, at 
visit 3, the subset of women treated with radiotherapy had significantly higher MNF. (Radiation 
by visit, p=0.0077). Women treated with radiation had overall higher frequencies (mean=0.073) 
than women who were not treated (mean=0.057) (p= 0.0004) 
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Discussion 
 
     In this longitudinal study we showed that MN/cytome abnormality frequencies in lymphocytes 
increase after treatment for breast cancer and remain at an increased level for at least a year 
following the initiation of treatment.  In addition to the timing of the receipt of therapy, other 
factors significantly associated with acquired MN/cytome instability frequencies were therapy 
regimens (types of chemotherapy and/or radiation), race, tumor characteristics (luminal B or triple 
negative tumors), and a subset of PNS (total perceived stress and cognitive flexibility domains).   
 
     The largest influences on lymphocyte MN/cytome abnormality frequencies were the 
chemotherapy and radiation treatments given to the participants and the time points of assessment 
relative to the administration of these treatments.  Since both of these types of treatment are 
genotoxic and can induce DNA damage, it is not surprising that they were associated with 
significant increases in MN/cytome abnormality frequencies.  At visit 2, during the administration 
of chemotherapy, women treated with TAC acquired the greatest increase in chromosomal 
instability levels.  The fact that the instability levels were higher in the TAC compared to TC 
treatment cohorts points to adriamycin as the primary factor contributing to this comparative 
increase.  Adriamycin is a member of the anthracyclin class of compounds.  Although this drug is 
widely used, the mechanism(s) for its effectiveness in preventing/reducing cancer cell proliferation 
is/are not fully known, with some investigators proposing that it induces cell apoptosis or 
senescence by inhibiting topoisomerase II, while others cite roles for DNA adduct formation, 
oxidative stress, ceramide overproduction and/or torsion-induced nucleosome destabilization as 
the causal means for this drug’s efficacy (Gewirtz 1999; Senchenkov , et al., 2001; Minotti, et al., 
 
 
59 
 
2004; Yang, et al., 2014). While the mechanism(s) of action for adriamycin (also known as 
doxyrubicin) remain(s) controversial, this drug has consistently been shown to induce 
chromosomal instability (Table 7), with telomere dysfunction also consistently being associated 
with this increase in acquired chromosomal abnormality frequencies (Elmore, et al., 2002; Khan, 
et al., 2009; Li, et al., 2012).   Thus, the results of our study are in agreement with the in vitro 
findings of several other investigators and the in vivo results of the few other groups reporting 
frequencies following treatment in humans. 
 
     While the cohort of participants receiving TAC treatment had the highest levels of 
chromosomal instability at time point 2, the cohort receiving TCH showed the highest overall 
change in MN proportion levels Table 4.  Explanations for this difference in MN/cytome 
abnormality frequencies between treatments based on the time of specimen collection may reflect 
the length of the chemotherapy regimen (e.g. the number of cycles for the treatment), the 
mechanism(s) of the drugs used (docetaxel causes microtubule depolymerization leading to 
apoptosis, the administration of Herceptin (a targeted monoclonal antibody that binds to the HER2 
receptor), and/or the follow-up radiation treatments administered. Radiation therapy was also 
identified to have a significant predictive influence on the women’s acquired lymphocyte 
chromosomal instability frequencies. As with Adriamycin, radiation exposure has been 
consistently associated with increased levels of chromosomal instability in human cells, primarily 
through in vitro study designs (Table 7).       
 
     An unexpected finding in this study was the significant predictive association of race on 
MN/cytome abnormality frequencies, with the Caucasian study participants having higher overall 
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instability frequencies than the African American participants. To our knowledge, associations 
between lymphocyte MN/cytome abnormality frequencies and race in women treated for breast 
cancer have not been previously reported. Also, there is a paucity of information available 
regarding MN frequencies in healthy subjects from different racial groups (Huen, et al., 2006). 
However, the results of population cytogenetics studies are controversial, with some investigators 
suggesting a difference in constitutional chromosomal abnormality frequencies between people 
from different racial backgrounds, while most have seen no clear or consistent differences 
(Sherman, et al, 2007; Hook, et al., 1999; Hook and Porter, 1977). It is interesting to note that 
African American women have been described to have significantly lower levels of dietary-related 
oxidative DNA damage than white women, suggesting that there may be race-related differences 
in the cellular processes involved in oxidative DNA damage recognition/repair (Watters et al 
2007).  While our step-wise statistical approach suggests this observation is an independent 
association, given the inter-relatedness of human epidemiology variables, one cannot fully rule out 
the possibility that it may be confounded by other factors, such as age or tumor characteristics. For 
example, the Caucasian women participating in this study were significantly older than the African 
American participants. This difference is consistent with data from the American Cancer Society, 
which shows that African American women develop more aggressive forms of breast cancer at 
younger ages and show a poorer prognosis than Caucasians. However, given that increasing age 
has consistently been shown to be positively correlated with MN frequencies in healthy women 
(reviewed by Fenech, et al., 2011; Volders-Kirsch, et al., 2011), it is possible that the age of the 
Causasian participants contributed to their observed increased rate of MN/cytome abnormalites.  
We also observed differences in annualized income levels and alcohol consumption rates between 
the racial groups in our study, with the Caucasian women having significantly higher incomes and 
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alcohol consumption practices than the African American women. Therefore, given the inter-
related nature of the data, the basis for the association between race and MN/cytome abnormality 
frequencies in this study is not clear. 
 
     One aspect of breast cancer that has been associated with racial differences is the proportion of 
breast cancer tumor sub-groups in African American compared to Caucasian populations (Carey, 
et al. 2006). While not significantly different, a trend toward a higher proportion of HER2 positive 
(18.2%) and triple negative (36.4%) tumors was noted in the African American participants in our 
study compared to those noted in the Caucasian participants. This trend is consistent with the 
pattern reported by Carey, et al (2006) in their study of women from North Carolina. The 
proportions of tumor sub-types among the African American and Caucasian women participating 
in this investigation were not significantly different from those reported by Carey, et al. (2006) 
(Table 7).  Thus, the breast tumors in our participants appear to be representative of those seen in 
larger populations. The treatment regimen for each study participant is determined, in large part, 
by her breast tumor characteristics. Therefore, if treatments are related to chromosomal instability 
levels, one might also anticipate detecting the presence of a relationship between tumor 
characteristics and acquired chromosomal changes. Indeed, our stepwise reduction model showed 
a predictive influence of tumor characteristics on MN/cytome abnormality frequencies for the 
subset of women having luminal B or triple negative tumors that appears to be a separate influence 
(beyond that of treatment).  The interesting observation of a potential influence of tumors on 
acquired chromosomal instability levels in peripheral blood is in agreement with the previous 
reports by other investigators who have consistently detected higher pre-treatment MN frequencies 
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in women (and men) having a variety of different types of cancer when compared to age-matched 
controls without cancer (reviewed by Fenech, et al.,  and Kirsch-Volders, et al. 2011).  
 
     The basis for the influence of tissue-specific tumors on acquired chromosomal instability levels 
in peripheral blood (and possibly other somatic tissues) is not clearly known. However, one factor 
that could contribute to this increase in our population is stress, since the baseline values were 
collected after the participants had received their diagnosis of cancer (but before treatment).  To 
our knowledge, this is the first study to identify a significant predictive association between stress 
and acquired lymphocyte chromosomal instability in women with breast cancer, with elevated 
stress levels being associated with higher frequencies of MN/cytome abnormalities. In the only 
other previous study in which a significant association was observed between stress and an 
increased rate of peripheral blood chromosomal instability, twins exposure to childhood sexual 
abuse were found to have significantly higher frequencies of MN than their unexposed identical 
co-twins (York et al. 2013). Furthermore, the data from the discordant identical twin study 
suggested that chromosomal instability accumulated throughout the lifespan of the twins exposed 
to childhood sexual abuse, leading the authors to speculate that the increased incidence of health 
problems observed in people experiencing early life trauma might be associated with acquired 
somatic chromosomal abnormalities (York, et al., 2013). While there is a paucity of studies 
investigating associations between stress and acquired chromosomal instability frequencies in 
women with breast cancer (or any type of cancer), several investigators have reported an 
association between stress and telomere shortening (Shalev et al 2013, Surtees et al. 2011); 
especially chronic stress (Quinlan et al 2014).  Given that telomere shortening has also consistently 
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been observed to result in increased frequencies of acquired chromosomal abnormalities, it follows 
that stress would also be associated with chromosomal instability.   
  
     A second PNS identified to have a significant predictive association with MN/cytome 
abnormality frequencies was cognitive flexibility domain measures. Given that cognitive 
flexibility domains have been one of the aspects of cognition impacted by chemotherapy (along 
with working memory, processing speed, multitasking, and attention)(Wefel et al 2012; Kesler et 
al 2013) this association was of particular interest. However, the relationship observed between 
chromosomal instability and cognitive flexibility domain measures was positive, with women 
having higher cognitive flexibility values also having higher chromosomal instability frequencies. 
Our initial hypothesis was that increased levels of soma-wide chromosomal instability could lead 
to the presence of a clone(s) with a chromosomal imbalance and that this imbalance would lead to 
compromises in cognitive function. Therefore, the observation of higher cognitive flexibility 
domains being predictive of higher MN/cytome abnormality frequencies seemed contradictory of 
our initial conjecture. This impression is based on the concept that higher MN/cytome abnormality 
frequencies are considered to be a negative outcome indicating the presence of chromosomal 
instability. However, an alternative interpretation is that these cytological structures serve as 
indicators that the cell has successfully recognized the presence of chromosomal instability and 
has eliminated the abnormality from the cell, thereby reducing/preventing the accumulation of 
DNA/chromosomal damage. Thus, it is feasible that women having higher MN/cytome 
abnormality frequencies in response to genotoxic agent exposures may actually have more 
efficient repair systems than women with lower MN/cytome abnormality values. Interestingly, the 
results from in vitro time-lapse studies have shown that the frequency of apoptosis is higher in 
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cells having a MN than cells without a micronucleus, suggesting that these cytome measures are 
related to cellular fate (Utani et al 2010).  While intriguing, this association between lymphocyte 
instability and cognitive flexibility warrants further study before clear conclusions can be derived.  
 
      In addition to the significant associations we observed, we also showed a lack of predictive 
associations for several factors. Of note, no significant association was observed between age and 
MN/cytome abnormality frequencies in this study. Other investigators have also failed to detect 
an age effect for MN frequencies in patients with cancer, or specifically with breast cancer, despite 
the clear association between age and MN frequencies that has consistently been observed in 
healthy adults (Table 7)(Fenech, et al., 2011; Kirsch-Volders, et al., 2011). This lack of a clear, 
independent influence of chronological age on lymphocyte MN frequencies in women with breast 
cancer could reflect the narrow age range of the participants sampled in this (and other studies) of 
women with breast cancer. Alternatively, the influence(s) of factors related to breast cancer 
development may over ride or “mask” the effects of age. For example, the large effects of the 
treatments may mask any impact attributable to age.  
 
     In summary, we determined that lymphocyte chromosomal instability frequencies increase in 
women following their treatment for breast cancer, with these increased frequencies persisting for 
at least one year following treatment. We identified 8 factors (time from treatment, the type of 
chemotherapy, radiotherapy, race, luminal B tumor sub-group, triple negative tumor sub-group, 
stress, and cognitive flexibility domains) that were predictive of these MN/cytome abnormality 
frequencies. Of particular interest was the recognition of stress as a contributor to increased levels 
of chromosomal instability since this factor has the potential to be modulated through intervention. 
 
 
65 
 
The recognition of biomarkers associated with the development/persistence of PNS, such as 
MN/cytome abnormality frequencies, could lead to a better understanding of the biological basis 
for the adverse side-effects associated with cancer treatment and could also provide a basis for the 
future development of an algorithm to identify individuals most “at risk” for acquiring PNS. 
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Chapter 3 
 
 
 
Acquired Epigenetic Changes in Women Treated for Breast Cancer: 
 
Methylation patterns in the peripheral blood. 
 
 
 
                                                                  Introduction 
 
Breast cancer (BC), which affects approximately 1 in 8 females in the US, is the most 
common invasive cancer in women (American Cancer Society, 2013). BC accounts for about 29% 
of women’s cancer and is the second most common cause leading to mortality in females 
(American Cancer Society. 2013, Siegel et al. 2014). Due to advances in early detection and 
management of BC, the survival rates for women with BC have steadily increased during the last 
two decades, culminating in an estimation of about 2.5 million BC survivors. However, a major 
subset of BC survivors develop short and long term side effects as result of their treatments, or the 
cancer itself. These side effects include anxiety (Badger et al 2007), depression (Badger et al 2007), 
fatigue (Berger et al. 2010), sleep disturbances (Lee et al 2004), pain (Utne et al 2010, Valeberg 
et al 2008), and cognitive dysfunction (Wefel et al 2011) and can be collectively referred to as 
psychoneurological symptoms (PNS).  While there is an essential need to retain and continue to 
enhance survivorship following treatment for BC, there is also a critical need to reduce the adverse 
side effects associated with BC and its treatment to allow for improvements in the quality of life 
for the survivors.  
            
     BC is a heterogeneous condition, making pathological diagnostic classifications, and, in turn, 
treatments decisions, challenging.  Moreover, significant variability in drug response and 
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outcomes has been observed in individuals treated with identical therapy regimens (Polyak et al 
2011, Westbrook & Stearns 2013). Gene expression analyses of tumor cells have resulted in 
improvements in recognizing optimal therapeutic approaches to be followed to prevent cancer cell 
proliferation and metastasis, but there is a paucity of information available about “personalized 
medicine” approaches to identify the prevalence or causes of the soma-wide adverse side effects 
that arise following treatments for BC (or the cancer itself) (Perou et al 2000, Sorlie et al 2001, 
Sorlie et al 2003; The Cancer Genome Atlas 2012, Byler et al. 2014).  An optimal approach for 
treating each person diagnosed with BC would not be determined solely by the classification of 
their tumor’s characteristics, but would also include recognition of the individual’s 
genetic/exposure-related susceptibility to cellular responses from the therapeutic agents 
(chemotherapy and radiation) being administered, as well as the potentially long term systemic 
cellular biological changes that might result from the tumor and its treatment, such as potential 
acquired epigenetic alterations.  
              
     Epigenetics is a relatively new, but very promising and rapidly growing area of research that 
has been suggested to be the epicenter of modern medicine since it provides explanations for the 
relationships between environment, genetic background and disease (Feinberg 2007, 2008). DNA 
methylation is one of the most stable and well-characterized epigenetic mechanisms (Jirtle and 
Skinner 2007). DNA methylation patterns in different tissues, including blood, are known to be 
sensitive to environmental insults, including (but not limited to) those associated with the aging 
process (Rakyan et al 2010, Teschendorff et al 2010) alcohol intake (Choi et al 2009, Christensen 
et al 2010) and smoking (Breitling et al 2011). It also plays an important role in inflammation 
(Wierda et al 2010), in developing cancers (Heyn and Esteller 2012) and in behavior/psychiatric 
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disorders (Mehler et al 2008, Narayan and Dragunow 2010). Typically, in normal cells, promoter 
CpG islands are hypomethylated, while repetitive DNA sequences in the genome are 
hypermethylated. Studies of genome-wide DNA methylation in cells from a wide range of 
different types of cancer have revealed that this typical scenario tends to be abnormally reversed 
(Feinberg et al 2006).  
 
     Investigations of DNA methylation patterns focused on BC tumors have been completed by 
several investigators, with their study results allowing for improvements in tumor classification, 
prognosis, and management (Szyf 2012, The Cancer Genome Atlas 2012, Byler et al. 2014, Van 
De Voorde et al 2012, Huang et al 2011).  DNA methylation patterns thought to be specific to the 
tumor have also been found in cell-free DNA (which is released from dead cancer cells) that is 
present in serum/plasma (Sidransky 2002, Van De Voorde et al 2012), with some investigators 
studying the association between targeted methylation patterns and prognosis, while others have 
monitored changes in targeted methylation patterns that arise in response to a treatment. However, 
the utility of assessing cell free DNA in serum/plasma is limited due to: (1) the inability to 
adequately/accurately follow-up a patient’s response to a treatment after the surgical removal of 
the tissue; and (2) the amount of presumed tumor-derived cell-free DNA in serum/plasma is very 
small and tends to lack sufficient quality (due to degradation) for use in the sensitive genetic 
techniques needed for genome-wide or targeted genetic/epigenetic evaluations. Thus, there is a 
need for an assay that can be used to evaluate potential associations between cellular responses 
that are acquired and persist following treatment for BC, with a goal of applying this technology 
to identify or stratify women who are most “at risk” for developing PNS or other adverse side 
effects following their treatment for BC. 
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     Given that the effects of chemotherapy and radiation have been shown to have a soma-wide 
impact, one approach for monitoring genetic and/or epigenetic changes that arise in response to 
therapy would be to study the patterns of cells in peripheral tissues. Furthermore, based on the 
conjecture that inflammation plays a key initiating role in the cascade of biological changes 
resulting from chemotherapy (as well as its ease of access for evaluation), peripheral blood seems 
to be a strong specimen for evaluating biological changes related to the acquisition of adverse side 
effects related to BC treatment. Few investigators have examined the association between BC - or 
cancer in general- and DNA methylation patterns in peripheral blood. However, the limited 
number of investigations published have indicated that peripheral blood is effective for identifying 
biomarkers indicative of an increased risk for developing breast cancer, and/or the presence of 
cancer (Wu et al 2011, Choi et al 2009, Cho et al 2010 , Wong et al 2010, Iwamoto et al 2011, 
Widschwendter et al 2008).  
 
    An important first step in understanding factors contributing to the 
acquisition/persistence of PNS in a subset of BC survivors is to identify biological changes that 
arise in women’s cells following their treatment for breast cancer and to determine if these changes 
vary with tumor characteristics and/or treatment regimens. We hypothesize that chemotherapy for 
BC leads to the acquisition of soma-wide epigenetic alterations and that these alterations can be 
detected in peripheral blood cells and will vary based on the type of chemotherapy administered. 
To test this hypothesis, we designed a longitudinal study to investigate acquired changes in 
methylation patterns in PBCs that were obtained from women diagnosed with BC; (1) before 
treatment (baseline) and (2) during the administration of different types of chemotherapy.   
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Materials and Methods 
 
Study Participant Ascertainment and Specimen Collection:  
     A total of 68 women with early stage (I to IIIA) breast cancer, who ranged in age from 23 to 
71, were ascertained through 5 regional cancer centers in Central Virginia, including the Massy 
Cancer Center (MCC) at Virginia Commonwealth University. To identify potential study 
participants, a member of the research team attended the weekly interdisciplinary Breast Health 
meetings at Virginia Commonwealth University Health System (VCUHS).  Study eligibility 
criteria for participants were: (1) gender (only females were included since too few male 
participants were available for study); (2) an age of 21 years or older; and (3) a diagnosis of early 
stage breast cancer with a scheduled visit to receive chemotherapy.  Exclusion criteria were: (1) a 
history of previous cancer, or chemotherapy; (2) a diagnosis of dementia;  (3) active psychosis; or 
(4) a history of immune-related diagnoses (e.g. multiple sclerosis and systemic lupus 
erythematosus). After providing their informed consent (VCU IRB #HM 13194), participants were 
enrolled and their first study visit was scheduled prior to the initiation of chemotherapy. Study 
visits took approximately one hour to complete. A peripheral blood sample was collected from 
each participant prior to the receipt of treatment (baseline or visit 1) and at the midpoint of the 
chemotherapy treatments (visit 2). The blood specimens were collected by venipuncture or through 
an existing access device.  The specimens were coded prior to their delivery (same day) to the 
cytogenetics lab to ensure that the geneticists completing this study were unaware of the clinical 
or treatment history of each participant at the time of sample processing and/or evaluation. 
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Chemotherapy Treatment Information 
 
     Medical records were used to determine chemotherapy treatments administered. The three 
primary types of chemotherapy regimens included: (1) Taxotere (docetaxel), Adriamycin 
(doxorubicin), and cyclophsophamide [TAC]; (2) Taxotere and Cyclophosphamide [TC]; or (3) 
Taxotere (docetaxel), Carboplatin (paraplatin); and Herceptin (transtuzumab) [TCH].  
 
DNA preparation and methylation assessment: 
     Genomic DNA was isolated from whole blood according to standard methods using the 
Puregene DNA Isolation Kit (Qiagen). An aliquot (500 ng per study participant) of DNA was then 
sent to Hudson Alpha Institute for Biotechnology for bisulfite conversion, using standard methods 
(Zymo Research EZ Methylation Kit) and genome-wide methylation pattern assessment, using the 
450K HumanMethylation Chip, according to the manufacturer’s protocol (Illumina).  The 450K 
HumanMethylation Chip interrogates 485,764 genome-wide targets. Both specimens (baseline and 
mid-chemo visits) from each study subject were localized to the same array to avoid any potential 
artifactual differences in methylation patterns that might arise due to “batch” effects. Also, to 
evaluate reproducibility of the assay and allow for the correction of any potential batch effects that 
might be present, replicate evaluations of a single specimen were completed (the same specimen 
was evaluated in every batch). Intensity data from the scanned arrays were imported into Illumina’s 
GenomeStudio software and the minfi Bioconductor (Aryee et al 2014, Gentleman et al 2004) in 
the R programming environment (R core team 2014) to obtain  values for each probe. 
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Genome-Wide Methylation Data Analyses 
Recognizing that high-throughput assays are subject to unwanted technical variation and that 
chemotherapy could elicit global DNA methylation changes, the functional normalization 
procedure was applied to the raw intensity values (Fortin et al 2014). Functional normalization 
builds upon quantile normalization by estimating the first 2 (default) principal components from 
inbuilt control probes as covariates to adjust for technical variation and is applied to the methylated 
and unmethylated intensities separately along with separate fits to the type I and type II probes; it 
has been shown to perform well even in the presence of batch effects. The primary motivation for 
this approach was to avoid placing unrealistic constraints across sample groups were likely to have 
very different marginal distributions (ie., pre- verus post-chemotherapy). In addition, since the 
performance of probes containing single nucleotide polymorphisms (SNPs) can be variable 
(Bibikova, et al., 2011), probes containing SNPs that overlapped the CpG site or at that were 
localized to the single base extension were excluded.  Because the intensity value, , reported for 
each CpG site represents “proportion methylated”, which is constrained to an interval value of 0 
to 1, where a  of 1 indicates complete methylation and 0 indicates no methylation, the normalized 
intensity values were transformed using the M-value procedure to promote normality (Du, et al., 
2010). The M-value is calculated as a logit transformation of the methylated and unmethylated 
intensity ratio along with an added term to offset potentially small values.  
 
Statistical analyses were then performed on the normalized M-values from the baseline 
compared to mid-chemotherapy samples. For each CpG site, differential methylation between 
baseline and treatment specimens was tested using a mixed effect linear model in the R 
programming environment (R Development Core Team, 2011), including a random effect term to 
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account for the paired status of observations. An additional term was included to account for the 
relative proportion of neutrophil levels (ie., the largest and most variable blood cell proportion) to 
account for changes in blood cell types that could differ between sample time points. This term 
controlled for a potential bias in results stemming from DNA methylation changes reflective of 
differences in white blood cell proportions following chemotherapy, but not the chemotherapy 
itself. To adjust for the multiple hypothesis tests, the p-values were used to estimate the false 
discovery rate (FDR) following Benjamini and Hochberg’s (1995) method. (Normalization of the 
data, calculation of the M-Values and detection of the differentially methylated sites were 
performed by Dr. York).  
 
The R program was then used to create pie charts and the DAVID gene functional 
classification tool (Huang, et al., 2007) was used to identify biological relationships among the 
differentially methylated sites. 
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Results 
 
A total of 68 women were initially included in the study and methylation patterns were analyzed 
in each woman before (Baseline=T1) and during chemotherapy (Mid-chemo =T2). A single paired 
sample showed lower median intensity values for both the unmethylated and methylated set of 
probes as compared to the other samples. Therefore, this participant’s specimens were excluded, 
resulting in a total of 67 paired samples that were analyzed. All women were diagnosed at early 
stage BC (I-IIIA). The women evaluated included 19 African Americans, and 48  Caucasians. The 
women were treated with either TAC (n=35), TC (n=22), or TCH (n=11). Using the normalization 
and SNP exclusion processes described in the methods section, a total of 18,131 probes were 
excluded from the analysis, resulting in a total of 467,633 probes that were evaluated for the paired 
specimens from each participant. 
 
Acquired alterations in methylation patterns were observed in response to chemotherapy 
(Figure 7). When methylation patterns were compared between visit one (baseline) and visit 2 
(mid-chemo), 1265 significant differentially methylated sites (DMSs) were detected (FDR<.01, 
<10% mean within pair difference) (Table 12). Acquired reduction in methylation (e.g. relative 
hypomethylaion) was seen more frequently than increases in methylation (relative 
hypermethylation) (Table 12 and Figure 8). A total of 788 of the 1265 significant differentially 
methylated CpG sites (62.3 %) showed relative hypomethylation following chemotherapy; while 
477 of 1265 CpG sites (37.7%) showed relative hypermethylation. Observed changes involved 
multiple types of sequences, but were most prevalent in the “open sea” regions of the genome for 
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both hypo & hyper methylated sites (Table 12 and Figure 8).  Of particular interest is the 
methylation status of the CpG island probes, since these sites are most clearly associated with gene 
function. Patterns differences showing increased methylation levels at the mid-chemo timepoint 
were observed in 8.0% of the CpG islands, with changes resulting in lower methylation values 
being seen in only 1.3% of the CpG islands. The significant DMSs showed altered patterns for 
genes involved in several biological processes or pathways including  (but were not limited to) 
those involved in transcription regulation, signal transduction pathways, immune response, 
hemostasis, neuronal regeneration, cell cycle and cell death (Tables 13-15). In particular, 51% of 
the DMSs were associated with phosphorylation processes (p=3.4x10-16). A subset of the 
significantly differentially methylated sites within interesting genes is listed in Table 16, along 
with a description of the genes’ biological functions.  
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Table 12: Distribution of acquired methylation changes in relation to genomic sites. 
        
Sites  
Island*             
N (%) 
N-Shelf* 
N (%) 
N-Shore* 
N (%) 
Open Sea* 
N (%) 
S-Shelf* 
N (%) 
   S-shore* 
    N (%) 
 
Total Significant; 1265  48 (3.8) 82 (6.5) 106 (8.4) 851 (67.3) 98 (7.7)    80 (6.3)  
Hypo; 788 (62.3 %) 10 (1.3) 55 (7.0) 61 (7.7) 545 (69.2) 69 (8.8)    48 (6.1)  
Hyper; 477 (37.7%) 38 (8.0) 27 (5.7) 45 (9.4) 306 (64.2) 29 (6.1)    32 (6.7)  
 
* CpG Island is defined as a DNA region > 500bp, GC >= 55% and observed/expected CpG ratio >.65 (Takai and 
Jones 2002). 
* Shore is 2 kb from CpG island. The N and S indicate upstream and downstream of the CpG island, respectively.  
* Shelf is 4-6 kb from CpG island.  The N and S indicate upstream and downstream of the CpG island, respectively. 
* Open sea > 6kb from CpG island 
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Figure 7: Variation in response to chemotherapy between women. Women with BC showed 
variability in acquired changes in DNA methylation patterns in response to chemotherapy, as 
indicated by the arrows.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Acquired epigenetic/chromosomal changes in women with breast 
cancer are associated with chemotherapy and the acquisition/
persistence of psychoneurological symptoms. 
Conclusions 
Background, Hypothesis and Aims 
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Department of Pathology 
What are the factors that associate with MNF ?  
Did leukocyte methylation patterns change with 
chemotherapy? 
Supported by NIH grant R01 NR012667 (D Lyon and C Jackson-Cook, PIs). 
Figure from Illumina 
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• The study showed 6 predictors of MNF: Visit, type of tumor, chemotherapy, radiation, race, 
& stress. 
• Micronuclei frequencies in women diagnosed with breast cancer increased after exposure 
to chemotherapy and radiation. Also, differences were observed based on the type of 
chemotherapy  received (AC higher than TC or TCH). 
• Decreases in MNF were observed after 1 year following treatment, but did not return to 
baseline levels. 
• White women had overall higher MNF as compared to African American women. 
• Women with more stress had higher MNF. 
• Methylation alterations were acquired in response to chemotherapy, with hypomethylation 
changes being seen most often; especially following AC. Changes were observed for 
multiple types of sequences for both AC and TC and were predominantly associated with 
RNA transcripts. 
 
 
Continuation of these studies may allow for the recognition of consistently acquired genomic/epigenomic 
alterations that contribute to the development and/or persistence of PNS in women treated for breast cancer. This 
knowledge could be used to identify  biomarkers for predicting a woman s risk for developing PNS, thereby 
empowering her to make informed decisions regarding treatment options. These studies may also provide the 
foundational basis for the development of targeted interventions to possibly alleviate or reverse the PNS 
associated with breast cancer and its chemotherapy.   
Women with HER2+ expression/treatment showed lower MNF. A significant increase in MNF 
was observed in the women following chemotherapy (V2) and following radiation (V3). A 
significant difference in MNF was also observed between chemotherapy regimens at V2:  AC > 
TC or TCH. 
(A) Variation in changes in methylation patterns were noted among patients. (B) Acquired 
hypomethylation was seen more often in women receiving AC vs TC.  (C) A trend toward more 
hypomethylation alterations involving CpG islands was observed with AC.  For both chemo 
types the m jority of cha g  occurred in open sea  sequences, followed by CpG shores and 
islands. (D) The majority of both AC & TC hyper- and hypomethylation changes occurred in RNA 
coding sequences. Using a FDR of 1%, 15,939 differentially methylated regions (3.4% of total 
array sites) were observed at mid-chemo compared to baseline time points. Specific genes that 
were noted to show altered patterns included (but were not limited to) those involved in DNA 
repair, transcription regulation, signal transduction pathways, and neuronal regeneration. 
    Treatment advances have resulted in improvements in survival for women diagnosed with 
breast cancer, but many of these survivors report acquiring persistent adverse side effects 
following treatment. These psychoneurological symptoms (PNS) include cognitive 
dysfunction, depression, anxiety, fatigue, sleep disturbances, and pain. The etiology of these 
PNS is not fully known. We offer the hypothesis that inflammatory activation is an early step 
in a cascade of biological changes leading to genomic and/or epigenetic alterations that 
contribute to PNS. Alternatively, epigenetic alterations may occur first, leading to 
inflammatory activation. These epigenetic changes could also lead to chromosomal 
instability. Each of these genomic/epigenetic factors, acting either singly or in concert, could 
contribute to the development/ persistence of PNS since they would provide a means for 
remembering  the biological effects after chemotherapy and have plasticity to explain 
responsiveness to environmental exposures (as well as G x E interactions). They also have 
the potential for reversibility, with the latter attribute being important for the potential 
development of therapeutic interventions.  
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MNF increase significantly following the initiation 
 of treatments as compared to baseline levels.  
              Factors predictive of MNF: 
1. Visit (p<.0001): MNF increase with treatment 
2. Chemotherapy (p=.0213): MNF highest in AC treated 
patients 
3. HER2+ (all received trastuzumab)(p=0.0012): MNF 
lower    
4. Radiation (p=.0185): Subset of women treated 
5. Race (p=.0129): C women had higher MNF than AA 
6. Stress (p=.0044): Women with more stress had higher 
MNF 
Goal, Study Design, Aims,  and Methods 
Specific Aims: 
The primary aims of this study were to 
collect blood specimens from women 
having a diagnosis of breast cancer 
and  longitudinally determine: 
1. The frequency of acquired 
chromosomal instability and genome-
wide epigenetic changes present at 
baseline and following treatments. 
2. The relationship between acquired 
chromosomal and/or epigenetic 
alterations and the development/
persistence of PNS. 
Investigate the biological basis for the development of  PNS associated with 
chemotherapy, or the cancer itself, in women treated for BC. 
Goal : 
Longitudinal+Study+Design:+(5+4me+points) 
(A) 
Methods: 
Aboalela N1, Lyon D2,, Elswick R2, York TP 1, Kelly DL2, Jackson-Cook C1,3 
1Department of Human and Molecular Genetics, 2School of Nursing,  3Department of Pathology, Virginia 
Commonwealth University, Richmond, VA 
! ! ! ! ! ! ! ! ! ! !
! ! !
Demographic,
,
A,American,, N=22, !! Caucasian, N=51, !!
! ! !
Measure, TAC! TC! TCH! TAC! TC! TCH! Total!
! ! !
!! (n=10),! (n=6)! (n=6)! (n=30)! (n=16)! (n=5)! (n=73)!
! ! !
Income, !! !! !! !! !! !! !!
! ! !
Less!than!30,000! 5!(22.73)*! 4!!(18.18)!!! 3!(13.64)! 6!!(11.76)! 1!!!(1.96)! 0! 19!!!!!(26.03)!
! ! !
30,000?59,999! 3!(13.64)! 2!!(9.01)! 3!(13.64)! 6!!(11.76)! 1!!!(1.96)! 0! 15!!!!!(20.55)!
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90,000+! 1!!!!(4.55)! 0! 0! 11(21.57)! 6!(11.76)! 2!!!(3.92)! 20!!!!!(27.40)!
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Status, ! ! ! ! !
!
!!
! ! !
!!
! ! ! ! ! !
!!
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Yes! 2!!!(9.01)! 3!!(13.64)! 2!!(9.01)! 5!!!(6.94)! 2!(2.77)! 1!!!(1.39)! 15!!!!(20.83)!
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No! 8!(36.36)! 3!!(13.64)! 4!(18.18)! 25(34.72)! 13!(18.06)! 4!!!(5.56)! 57!!!!(79.17)!
! ! !
!!
! ! ! ! ! !
!!
! ! !
Current,Ethanol,
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! ! !
!!
! ! ! ! ! !
!!
! ! !
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! ! !
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  a) Sites with relative Hypo/Hyper methylation         b) Acquired alterations in DNA methylation 
 
 
 
 
 
 
 
 
               c) relatively hypomethylated sites                               d) relatively hypermethylated sites 
 
Figure 8: Significant acquired alterations in methylation patterns in peripheral blood cells 
following chemotherapy.   
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A total of 1265 significantly DMRs were detected at (FDR= 0.01 and >10% mean within pair 
difference) (a) sites with relative hypomethylation (62%) were acquired more frequently than 
hypermethylation (37.7%). (b) Acquired alterations in DNA methylation were distributed across 
different genomic sequences with the majority occurring in the open sea sequences (67.3%), 
followed by N-shore (8.4%), S-Shelf (7.7%), N-shelf (6.5%), S-shore (6.3%), and Islands 
(3.8%). (C) & (D) Distribution of acquired relative hypo & hyper methylation across the 
different sequences. Both were mainly involved in the open sea sequences (69.2% & 64.2%) 
respectively. More acquired hypermethylation alterations were acquired at CpG islands (8%) 
when compared to acquired hypomethylation (1.3%). 
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Table 13.  Subset of Functional Roles Associated with the Significantly DMSs (based 
on Keywords)* 
 
Term 
Genes with DMSs  
 
P-Value 
 
 
Benjamini 
# % 
Phosphoprotein 325 51.1 3.9E-16 1.5E-13 
Cytoplasm 154 24.2 2.5E-7 5.5E-5 
Activation of Protein Kinase Activity 16 2.5 6.9E-6 1.7E-2 
Positive Regulation of Transferase Activity 24 3.8 7.3E-6 9.2E-3 
Alternative Splicing 287 45.1 8.4E-6 1.3E-3 
Negative Regulation of Gene Expression 38 6.0 8.6E-6 7.2E-3 
Positive Regulation of Kinase Activity 23 3.6 1.3E-5 8.0E-3 
Splice Variant 285 44.8 1.9E-5 3.3E-2 
Regulation of Phosphate Metabolic Process 36 5.7 2.2E-5 1.1E-2 
Regulation of Phosphorus Metabolic Process 36 5.7 2.2E-5 1.1E-2 
Positive Regulation of Protein Kinase Activity 22 3.5 2.4E-5 9.9E-3 
Sequence Variant 425 66.8 2.7E-5 2.3E-2 
Polymorphism 409 64.3 4.1E-5 4.6E-3 
Regulation of Phosphorylation 34 5.3 5.4R-5 1.9E-2 
Mutagenesis Site 96 15.1 6.2E-5 3.6E-2 
Intracellular Signaling Cascade 69 10.8 6.8E-5 2.1E-2 
Regulation of Transferase Activity 29 4.6 7.0E-5 2.0E-2 
Regulation of Protein Amino Acid Phosphorylation 18 2.8 8.3E-5 2.1E-2 
Regulation of Kinase Activity 28 4.4 8.7E-5 2.0E-2 
Negative Regulation of Transcription 33 5.2 9.4E-5 2.0E-2 
Repressor 30 4.7 1.2E-4 1.0E-2 
ATP-Binding 67 10.5 1.2E-4 8.9E-3 
Regulation of Protein Kinase Activity 27 4.2 1.2E-4 2.4E-2 
Coiled Coil 93 14.6 1.4E-4 8.8E-3 
Transcription Activator Activity 30 4.7 1.8E-4 1.3E-1 
Chromosomal Rearrangement 22 3.5 2.0E-4 1.1E-2 
Zinc Finger, C3HC4 RING-Type 20 3.1 2.1E-4 2.0E-1 
Transferase 68 10.7 2.9E-4 1.4E-2 
Negative Regulation of Transcription from RNA Polymerase II 
Promotor 
22 3.5 3.0E-4 5.2E-2 
Calcium Transport 11 1.7 3.2E-4 1.4E-2 
Type II Diabetes Mellitus 9 1.4 3.8E-4 5.3E-2 
Phosphorus Metabolic Process 54 8.5 4.0E-4 6.5E-2 
Negative Regulation of Transcription, DNA-Dependent 36 4.1 4.8E-4 7.3E-2 
Nucleotide-Binding 78 12.3 4.8E-4 1.9E-2 
Pleckstrin Homology-Type 23 3.6 4.9E-4 2.3E-1 
Nucleoplasm 49 7.7 4.9E-4 1.8E-1 
Phosphatidylinositol Signaling System 11 1.7 5.0E-4 3.6E-2 
Binding Site: ATP 33 5.2 5.1E-4 2.0E-1 
Limb Morphogenesis 12 1.9 5.2E-4 7.4E-2 
Appendage Morphogenesis 12 1.9 5.2E-4 7.4E-2 
Nucleotide Binding 105 16.5 5.4E-4 1.8E-1 
Kinase 39 6.1 5.5E-4 2.0E-2 
Phosphorylation 46 7.2 5.7E-4 7.7E-2 
Calcium Channel 9 1.4 6.0E-4 2.0E-2 
Phosphotransferase 17 2.7 6.1E-4 1.9E-2 
Negative Regulation of RNA Metabolic Process 26 4.1 6.2E-4 7.9E-2 
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Positive Regulation of JUN Kinase Activity 7 1.1 6.3E-4 7.7E-2 
Protein Amino Acid Phosporylation 40 6.3 6.3E-4 7.3E-2 
Negative Regulation of Nucleobase, Nucleoside, Nucleotide and 
Nucleic Acid Metabolic Process 
33 5.2 6.6E-4 7.3E-2 
Embryonic Limb Morphogenesis 11 1.7 7.1E-4 7.5E-2 
Embryonic Appendage Morphogenesis 11 1.7 7.1E-4 7.5E-2 
Appendage Development 12 1.9 7.3E-4 7.4E-2 
Limb Development 12 1.9 7.3E-4 7.4E-2 
Positive Regulation of Macromolecule Metabolic Process 48 7.5 7.5E-4 7.3E-2 
Adenyl Nucleotide Binding 78 12.3 7.7E-4 1.7E-1 
Negative Regulation of Nitrogen Compound Metabolic Process 33 5.2 8.3E-4 7.7E-2 
Zinc-Finger 78 12.3 8.3E-4 2.4E-2 
Pleckstrin Homology 21 3.3 9.3E-4 2.8E-1 
Nucleoside Binding 79 12.4 9.3E-4 1.6E-1 
Regulation of Transcription from RNA Polymerase II Promotor 42 6.6 9.6E-4 8.6E-2 
Apoptosis 25 3.9 9.7E-4 2.7E-2 
*Subset selected to include only those associations having a P-value of E-4 or smaller 
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Table 14. Biological Pathways Associated with the significantly DMSs (Panther 
pathways search). 
 
 
Term 
Genes with DMSs  
 
P-Value 
 
 
Benjamini 
# % 
PDGF Signaling Pathway 20 0.3 6.5E-4 5.7E-2 
Endothelin Signaling Pathway 13 0.2 1.3E-3 5.7E-2 
Inflammation Mediated by Chemokine and Cytokine Signaling 
Pathway 
25 0.4 7.0E-3 1.9E-1 
T Cell Activation 13 0.2 9.9E-3 2.0E-1 
Angiotensin II-Stimulated Signaling Through G Proteins and 
Beta-Arrestin 
8 0.1 1.0E-2 1.7E-1 
VEGF Signaling Pathway 10 0.2 1.0E-2 1.4E-1 
B Cell Activation 10 0.2 1.7E-2 2.0E-1 
Integrin Signaling Pathway 18 0.3 2.6E-2 2.6E-1 
Vitamin D Metabolism and Pathway 4 0.1 4.3E-2 3.6E-1 
Purine Metabolism 3 0.0 5.1E-2 3.8E-1 
Ras Pathway 9 0.1 6.0E-2 4.0E-1 
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Table 15. Biological Pathways Associated with the significantly DMSs (KEGG 
pathways search). 
 
 
Term 
Genes with DMSs  
 
P-Value 
 
 
Benjamini 
# % 
Type II Diabetes Mellitus 9 0.1 3.8E-4 5.3E-2 
Phosphatidylinositol Signaling System 11 0.2 5.0E-4 3.6E-2 
Gap Junction 11 0.2 2.1E-3 9.8E-2 
Natural Killer Cell Mediated Cytotoxicity 13 0.2 5.1E-3 1.7E-1 
Regulation of Actin Cytoskeleton 17 0.3 8.7E-3 2.2E-1 
Chemokine Signaling Pathway 15 0.2 1.3E-2 2.7E-1 
GnRH Signaling Pathway 10 0.2 1.3E-2 2.4E-1 
mTOR Signaling Pathway 7 0.1 1.4E-2 2.3E-1 
MAPK Signaling Pathway 19 0.3 1.5E-2 2.1E-1 
Small Cell Lung Cancer 9 0.1 1.5E-2 2.0E-1 
Non-Small Cell Lung Cancer 7 0.1 1.7E-2 2.0E-1 
Renal Cell Carcinoma 8 0.1 1.8E-2 2.0E-1 
Focal Adhesion 15 0.2 2.3E-2 2.3E-1 
T Cell Receptor Signaling Pathway 10 0.2 2.3E-2 2.2E-1 
VEGF Signaling Pathway 8 0.1 2.5E-2 2.2E-1 
Oocyte Meiosis 10 0.2 2.6E-2 2.1E-1 
Vascular Smooth Muscle Contraction 10 0.2 2.9E-2 2.2E-1 
Fructose and Mannose Metabolism 5 0.1 4.1E-2 2.9E-1 
Prion Diseases 5 0.1 4.5E-2 3.0E-1 
Long-Term Potentiation 7 0.1 4.7E-2 2.9E-1 
Neurotrophin Signaling Pathway 10 0.2 5.0E-2 3.0E-1 
Apoptosis 8 0.1 5.1E-2 2.9E-1 
Chondroitin Sulfate Biosynthesis 4 0.1 5.1E-2 2.8E-1 
Nicotinate and Nicotinamide Metabolism 4 0.1 6.4E-2 3.3E-1 
Dilated Cardiomyopathy 8 0.1 6.5E-2 3.2E-1 
Chronic Myeloid Leukemia 7 0.1 6.9E-2 3.3E-1 
Aldosterone-Regulated Sodium Reabsorption 5 0.1 7.3E-2 3.3E-1 
Type I Diabetes Mellitus 5 0.1 7.8E-2 3.4E-1 
Calcium Signaling Pathway 12 0.2 7.8E-2 3.4E-1 
Fc Epsilon RI Signaling Pathway 7 0.1 8.1E-2 3.3E-1 
Pathways in Cancer 19 0.3 8.3E-2 3.3E-1 
Toll-Like Receptor Signaling Pathway 8 0.1 9.6E-2 3.7E-1 
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Table 16. Summary of a subset of genes differentially methylated in patients treated for breast cancer 
1Functional descriptions obtained from DAVID clustering.  
GENE NAME (ABBREVIATION) DESCRIPTION OF FUNCTION1 LOCATION2 
RAD52 homolog (S. cerevisiae) 
RAD52 
Cell cycle, Interact with DNA recombination  protein 
RAD51 
12: 1,021,255 
RAD51-like 1 (S. cerevisiae) 
(RAD51L1) 
Cell cycle,  Nucleotide and ATP binding 14:68,286,496 
phosphoinositide-3-kinase, 
catalytic, delta polypeptide 
(PIK3CD) 
Apoptosis,  Nucleotide and ATP binding,  Intracellular 
signaling cascade,  Transferase 
1:9751525 
MAD1 mitotic arrest deficient-like 
1 (MAD1L1) 
Regulate cell cycle 7:1937325 
retinoic acid receptor, alpha 
(RARA) 
Cytokine production, immune response,  Intracellular 
signaling cascade,  Zinc ion binding 
17: 38497640 
histone deacetylase 4 (HDAC4) Regulator of cell proliferation, Cell death ,  Zinc ion 
binding 
2:240016312 
Janus kinase 1 (JAK1) Nucleotide and ATP binding, Intracellular signaling 
cascade,  Transferase 
1:65298906 
v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) (ETS1) 
Regulate cell cycle, Cell death, regulator of cell 
proliferation, immune response,  Cell migration 
11:128328656 
Beta dystrobrevin (DTNB) Zinc ion binding, ion binding 2:25600067 
Vascular endothelial growth factor 
receptor 1 (FLT1) 
Regulator of cell proliferation,  Cell migration,  
Nucleotide and ATP binding,  Intracellular signaling 
cascade,  Transferase 
13:28874483 
deoxynucleotidyltransferase, 
terminal (DNTT) 
Transferase, ion binding  10:98064085 
tumor protein p63 (TP63) Cell death, regulator of cell proliferation, cell-cell 
signaling,  Neuron projection,  Intracellular signaling 
cascade,  Zinc ion binding 
3:189349216 
ubiquitin-conjugating enzyme E2, 
J2 (UBC6 homolog, yeast) 
(UBE2J2) 
Nucleotide and ATP binding 1:1189292 
DNA (cytosine-5-)-
methyltransferase 3 alpha 
DNMT3A 
Transferase,  Zinc ion binding 2:25455830 
SMAD family member 3 (SMAD3) Transcription factor in the TGF-B pathway,positive 
regulator of cytokine production, cell death & 
proliferation regulator, regulate cell cycle, immune 
responce 
15:67458493 
tumor necrosis factor (ligand) 
superfamily, member 10 
(TNFSF10) 
Induction of apoptosis, cell- cell signaling, immune 
response,  Zinc ion binding 
3:172223298 
tumor necrosis factor (TNF 
superfamily, member 2) (TNF) 
Regulate cell cycle , Induction of apoptosis, cytokine 
production, regulator of cell proliferation, immune 
response,  Cell migration,  Intracellular signaling 
cascade 
6:31543344 
Interleukin 1; alpha (IL1A) Regulate cell cycle, cell death, Cytokine production, 
regulator of cell proliferation, immune response 
2: 113.531492 
Interleukin 18; interferon-gamma-
inducing factor (IL18) 
Cytokine production, regulator of cell proliferation,  
cell cell signaling, involved in behavior, immune 
response 
11:112013974 
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2Chromosome starting nucleotide position 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interlaukin 1 family member 6 & 
epsilon (IL1F6) 
Immune response 2:113763038 
Ataxin 1 (ATXN1) Cell death,  cell cell signaling,  involved in behavior,  
neurological system process 
6:16299343 
Huntingtin (HTT), Cell death, cell cell signaling,  involved in behavior,  
Neuron projection,  neurological system process 
4: 3076408 
the myosin heavy chain 10 non 
muscle (MYH10) 
Neuron projection,  neurological system process, Cell 
cycle, Cell migration,  Nucleotide and ATP binding 
17:8377523 
Myelin basic protein (MBP) Cell-cell signaling, immune response,  Neuron 
projection, neurological system process 
18:74690789 
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Discussion 
 
     The current longitudinal study shows that epigenetic alterations are present in peripheral blood 
obtained from women with BC following their receipt of chemotherapy. This data indicates the 
feasibility of using peripheral blood to assess an individual’s soma-wide cellular response to 
different types of treatment regimens.  To our knowledge, this is the first longitudinal study 
investigating the effect of chemotherapy on methylation patterns in peripheral blood obtained from 
women with BC before and after the administration of chemotherapy. We detected 1265 
significant DMSs (both increases and decreases in methylation) associated with chemotherapy, 
with the majority of changes showing decreases that involved multiple types of sequences. The 
observed alterations associated with chemotherapy, included changes in genes involved in the 
immune response, transcription regulation, signal transduction pathways, neuronal regeneration, 
as well as genes involved in learning and behavior.  
 
     The observed acquired alterations in methylation could be directly caused by the chemotherapy. 
Alternatively, they could reflect a cascade of cellular reactions that occurred in response to 
chemotherapy, such as inflammation. Our use of a longitudinal study design enabled us to make 
direct comparisons within individuals to identify alterations associated with the administration of 
chemotherapy, without needing to adjust the data for potential confounding effects attributable to 
co-factors such as age, race, income, alcohol intake and smoking status, tumor characteristics, and 
other comorbidities. However, one biological factor that was adjusted for in the analysis was 
changes in the proportions of white blood cells that might arise following chemotherapy, the latter 
of which mainly affected the neutrophil cell counts.  
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     We have identified only one other study in which investigators reported methylation changes 
in blood cells following exposure to chemotherapy. In that report, Smith et al. 2014, compared 
methylation patterns in peripheral blood mononucleated cells from 22 women treated with 
chemotherapy and compared their patterns to those of 39 women who were not treated with 
chemotherapy. These investigators detected only 8 DMSs that were significantly associated with 
chemotherapy, with each of these 8 sites showing lower methylation values in response to 
chemotherapy. Methylation on these sites was also associated with levels of inflammation. Given 
that many other factors differed between the treated and non-treated women evaluated in their 
study (including but not limited to different genetic/epigenetic backgrounds; environmental 
histories; lifestyle histories), their ability to detect differences attributable to chemotherapy was 
compromised. Nonetheless, it may not be fortuitous that we also observed decreased methylation 
values for 6 of the 8 DMSs identified by the Smith, et al research team [(TMEM49; cg12054453), 
(TMEM49; cg18942579), (TMEM49; cg16936953) (DTNB; cg25446789), (SMAD3; 
cg05438378) and (cg13518625)]. The increased number of significant DMSs associated with 
chemotherapy that was observed in our study as compared to theirs could be due to many reasons. 
First, one would expect more than 8 DMSs to be significantly associated with chemotherapy 
exposure including sites that are involved in mitosis, cell death, gene regulation, immunity and 
inflammation. However, probably due to the small sample size in their study,  as well as the 
difficulty inherent with detecting differences between women having different genetic/epigenetic 
backgrounds; environmental histories; lifestyle histories, as noted above,  they were limited in 
their ability to detect significant DMSs. Second, they compared treated to non-treated patients, 
which is a very big limitation of their study that prevented them from establishing a direct cause 
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and effect relationship between the observed differences and the treatment.  Lastly, they used the 
strict Bonferroni criterion for significance (p<1.03x10-7), while we used the FDR recommended 
by Benjamini and Hochberg’s significant at both an FDR of 0.01 and >10% mean within pair 
difference). When a more strict significance level was used in our study (FDR of 0.01, >20% mean 
within pair difference), only 145 significant DMSs were detected.  
 
     The significantly DMSs identified in our study included sites that were localized to genes that 
have functions that are congruent with anticipated responses to chemotherapy. These included 
clusters of genes involved in the cell cycle, cell death, signal transduction, hemostasis, 
transcription regulation, immune response and neurogenesis. Interestingly, we observed 
methylation changes involving at least 25 genes having functions related to the immune system, 
such as increases in the methylation levels of the tumor necrosis factor (TNF) gene, as well as 
decreases in the methylation values for the tumor necrosis factor (ligand) superfamily member 10 
(TNFSF10); Interleukin 1; alpha (IL1A); Interleukin 18; interferon-gamma-inducing factor 
(IL18); Interleukin 1 family member 6; and epsilon (IL1F6). The DMSs also included sites within 
at least 20 genes involved in neurogenesis, learning, memory and behavior, including decreased 
levels of methylation for sites localized in genes for Ataxin 1 (ATXN1) & Huntingtin (HTT), as 
well as increased methylation values for sites localized to the myosin heavy chain 10 non muscle 
(MYH10) and Myelin basic protein (MBP) genes.  
 
     Following chemotherapy in our cohort, the distribution of the significant DMSs across the 
genome revealed that both increases and decreases in methylation values occurred mainly in sites 
localized to “open seas” portions of the genome, but also occurred, albeit in lower percentages, in 
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the islands, shores, and shelves. Overall, more decreases in methylation were observed than 
increases in methylation.  
 
           While there is a paucity of reports of methylation changes in peripheral blood, methylation 
patterns present in tumor cells have been more widely studied. Overall, hypermethylation has often 
been observed at CpG islands localized to promoter regions of important tumor suppressors, while 
hypomethylation has often been observed globally and has been associated with genomic 
instability. The distribution of altered DNA methylation that contributes to tumorigenesis has been 
found to frequently happen in CpG islands, shores and shelves (Doi et al 2009, Irizarry et al 2009, 
Ogoshi et al 2011, Shen et al 2013). Less is known about methylation patterns in peripheral blood 
cells obtained from women with breast cancer at baseline. However, based on the limited number 
of available studies, global hypomethylation in peripheral blood cells has been observed to be 
associated with the presence of BC (Choi et al 2009). Also, methylation of specific loci have shown 
promise for use as markers for the presence of BC or an increased risk for developing BC (Iwamoto 
et al 2011, Wong et al 2010, Brennan et al 2012, Widschwendter et al 2008).  
      
     In summary, chemotherapy for BC, appears to impact the methylation patterns of peripheral 
blood cells, with alterations being observed that involve different biological pathways, including 
those involved in the immune system, cell death, transcription regulation, neurogenesis, cell cycle 
and signal transduction. These study results highlight the importance of further investigation to 
assess the role of acquired epigenetic changes in the cellular response to chemotherapy and its 
relation with inflammation, and also with the development of PNS. 
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These results support the premise that chemotherapy for BC leads to soma-wide alterations in 
epigenetic patterns. Further studies confirming these findings and comparing the acquired 
epigenetic alterations with acquired PNS following chemotherapy could provide insight about the 
biological changes underlying a person’s propensity to develop adverse side effects following 
chemotherapy. Ultimately, these types of studies could lead to the development of tests to identify 
women most at risk for acquiring cancer or cancer treatment related side effects and could lead to 
“personalized medicine” approaches that might improve the quality of their life for BC survivors.  
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Chapter 4 
 
 
 
Chromosomal Aberrations in Women with Breast Cancer 
 
Copy number aberrations in breast tumor tissues. 
 
 
 
Introduction 
 Breast cancer (BC) is a diagnosis that is shared by many women, since it is one of the most 
common cancers diagnosed in females (Siegel, et al. 2014). However, the clinical course 
associated with a diagnosis of BC varies markedly among these women. These differences in 
outcome have prompted pathologists and other scientists to study the characteristics of BC tumors 
in order to improve prognostication and therapy-decision making strategies. In particular, genetic 
research has revealed significant differences in the molecular “signatures” of tumors, the latter of 
which have served as the basis for improvements in BC classification and management (Polyak, 
2011).   
     The types of genetic abnormalities observed in BC tumors include mutations, copy number 
alterations (CNAs), changes in gene expression, and epigenetic alterations. Of the genetic markers, 
gene expression profiles in tumors have been most heavily utilized in directing decisions regarding 
treatment regimens and prognosis assessments (Byler, et al. 2014; Sinn et al. 2013). The most well 
studied BC tumor subtypes are the gene expression intrinsic subtypes, which mostly overlap with 
the status of the progesterone (PR), estrogen (ER), and human epidermal growth factor 2 (HER2) 
receptors.  These subtypes include (but are not limited to); Luminal A (Lum A), Luminal B (Lum 
B), HER2+, and triple negative [TNBC]).  
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      In addition to gene expression changes, copy number alterations, loss of heterozygosity (LOH) 
and allelic imbalances are common characteristics of solid tumors, including BC. Studies utilizing 
comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) arrays 
have allowed for enhancements in our ability to identify copy number alterations (CNAs) and 
allelic imbalances associated with the molecular intrinsic subtypes (The Cancer Genome Atlas 
2012). CNAs in tumors have also been associated with their gene expression patterns (Chin et al. 
2006, Pollack et al. 2002, Han et al. 2008).  
     One challenge investigators have encountered when assessing CNAs (or other genetic changes) 
in BC tumors is that these cells do not always proliferate well in vitro, and the tissue culture process 
can be associated with the acquisition of genetic/epigenetic patterns that were not present in the 
tumor in vivo.  An alternative approach is to study formalin fixed, paraffin embedded (FFPE) tissue 
that is directly obtained from the tumor. However, FFPE tissue typically has degraded DNA (as a 
result of fixation/embedding processes). Also, there is a limited quantity of DNA available for 
evaluation from FFPE specimens.  These technological hurdles have thwarted progress in 
identifying CNAs associated with clinical outcomes. Nonetheless, a limited numbers of 
investigators have successfully reported highly promising results showing relationships between 
CNAs in BC tumors and clinical course (Bergamaschi et al 2006, Chin et al 2006, Van et al 2006). 
Recently, the utilization of molecular inversion probe (MIP) technology has facilitated the 
assessment of CNAs in FFPE tissue (Thompson et al 2011). Using the MIP technology, researchers 
studying BC were able to associate tumor CNAs with the patient’s outcome, and have identified 
19 CNAs that discriminate recurrence risk in early stage BC (Thompson et al 2011). 
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Investigations of the peripheral blood (PB) of patients with cancer, has revealed the presence of 
an increase in chromosomal instability and epigenetic alterations that are not only present in the 
tumor tissue, but are also observed in the patient’s non-cancerous tissues. Many investigators have 
shown the presence of chromosomal anomalies (Barrios et al 1991, Trivedi et al 1998, Gebhart et 
al 1993, Pathak et al 1991, Udayakumar et al 1994, Rossner et al, 2005), and high levels of MN 
(Santos et al., 2010, Cardinale, et al. 2012) in the PB of patients with solid tumors. However, few 
investigators have examined the association between BC - or cancer in general- and DNA 
methylation patterns in PB. Also, there is a limited number of investigations published that 
compared chromosomal instabilities levels in tumors to those in blood. Therefore, it is of value to 
know if PB could be used as an easily accessible surrogate model for detecting genetic aberrations 
present in patients with solid tumors or to see if PB values could aid in identifying a person who 
has a high risk for developing cancer or the existence of a tumor.  
 
We hypothesis that chromosomal CNAs present in the tumor tissue associate with acquired soma 
wide chromosomal changes in other tissues such as the PB. Thus, utilizing the recently available 
MIP technology (Oncoscan), chromosomal alterations in the tumor tissue were investigated, in 
order to test their associations with soma wide chromosomal alterations in the PB.  
 
 
 
 
 
 
94 
 
Materials and Methods 
 
Study Participant Ascertainment and Specimen Collection:  
 
      For this pilot study a total of 17 women with early stage (I to IIB) breast cancer, who ranged 
in age from 41 to 63, were ascertained through the Massy Cancer Center (MCC) at Virginia 
Commonwealth University.  These women were participants in a larger study that is being 
completed by our research team to determine potential associations between chemotherapy 
treatment for breast cancer, acquired chromosomal and/or epigenetic alterations, and the womens’ 
development and persistence of psychoneurological side effects. The inclusion criteria for the 
larger study was : (1) 21 years or older;  (2) diagnosis of early stage breast cancer with a scheduled 
visit to receive chemotherapy; and (3) female gender (males were excluded since too few male 
participants were available for study).  Exclusion criteria included: (1) a history of previous cancer, 
or chemotherapy; (2) a diagnosis of dementia;  (3) active psychosis; or (4) a history of immune-
related diagnoses (e. g. multiple sclerosis; systemic lupus erythematosus).  Women who provided 
their informed consent (VCU IRB #HM 13194), to participate in the larger, parental study were 
recontacted to determine if they were interested in having tissue from their tumors evaluated in 
this pilot study.  Following their informed consent, the tumor specimens studied were obtained 
from the pathology lab via the Tissue & Data Acquision & Analysis Core (TDAAC) within the 
Department of Pathology at VCUHS. Peripheral blood specimens were collected by venipuncture 
or an existing access device prior to the initiation of chemotherapy. All specimens were coded 
prior to ensure that the cytogeneticists were unaware of the clinical history of each participant at 
the time of sample processing and evaluation. 
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Macrodissection  of  tumor tissue and tumor DNA extraction:  
    Tissue sections were prepared and reviewed by a pathologist, who identified the areas of the 
tissue that contained tumor to guide the macrodissection of the specimens.  In addition to an H&E 
slide denoting the location of tumor, the laboratory received 5 unstained slides from the adjacent 
tissue. Deparaffinization was performed using the Protocol SafeClear (Xylene substitute from 
Fisher). Each of the deparaffinized, unstained slides was then aligned on top of the marked 
matching H&E stained slide. The tumor area was then marked from the back of the slide. A 
disposable blade was used to remove the non-tumor tissue. The remaining marked tumor tissue 
was scrapped off and transferred into a labeled 2.0 µl Sarstedt tube. FFPE Genomic DNA 
extraction (including tissue lysis, DNA purification and elution) was performed using the QIAamp 
DNA FFPE tissue kit, as recommended for the Oncoscan Assay following the manufacturer’s 
protocol. Quantification of the eluted FFPE DNA was done using the Qubit ds DNA HS Assay Kit 
according to the manufacturer’s instructions.  
Tumor tissue copy number and somatic mutation analyses: 
A total of 6 µl of DNA, at a concentration of 12ng/ul, was prepared for the processing of the 
OncoScan FFPE Assay (Affymetrix). This array allows the sample(s) to be interrogated for 
genome-wide copy number alterations, genome-wide LOH, and targeted mutations. This assay, 
which utilizes molecular inversion probe (MIP) technology, provides CNA assessments of 
approximately 900 cancer-related genes, with a resolution that ranges between 50kb-125kb. In 
addition, it provides genome-wide coverage with a resolution that ranges between 300-380 kb. The 
array also allows for the detection of 74 actionable somatic mutations from 9 different genes 
(BRAF, KRAS, EGFR, IDH1, IDH2, PTEN, PIK3CA, NRAS, TP53). Genome-wide LOH can 
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also be evaluated usng this platform (with a resolution of 3MB-10MB). However, we elected to 
exclude the assessment of LOH in this pilot study since we did not have data for paired normal 
and tumor specimens.  All aspects of the OncoScan assay were performed following the 
manufacturer’s instructions.  
Peripheral Blood Chromosome Instability Methodology: 
      Baseline levels (prior to the administration of therapy) of chromosomal instability present in 
peripheral blood were quantified for each pilot study participant using the cytokinesis-block 
micronucleus (CBMN) and cytome assay (Fenech, 2006). A micronucleus (micronuclei) (MN) 
is(are) a small chromatin containing structure(s) juxtaposed to a parent nucleus. The CBMN assay 
was selected for the chromosomal instability assessments because it allows for: (1) the 
quantification of both numerical and structural cytogenetic findings; (2) the analysis of a large 
number of cells, thereby enhancing one’s ability to detect even low levels of instability; and (3) 
minimization of in vitro growth selection  (only 1 round of cell division is completed in vitro) and 
minimization of technical artifacts due to processing (for example, the CBMN assay does not show 
chromosome “loss” due to cell breakage at harvesting or slide making, which can occur when 
assessing metaphase chromosomes).  
     
      Leukocytes, which were isolated using Histopaque-1077 (Sigma), were established in culture 
according to the protocol of Fenech (1993).  Briefly, following their mitogenic stimulation using 
phytohemaglutinin (PHA), lymphocytes were arrested at cytokinesis by adding cytochalasin B to 
the cells 44 hr after their culture initiation. The cells were harvested 72 hours after culture initiation 
and slides prepared (2 per specimen) as described previously (Leach and Jackson-Cook, 2001).   
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 Micronuclei, buds, and/or bridges were visualized following giemsa staining (4% Harleco 
Giemsa solution) and identified according to the criteria established by Fenech (2006)(Figure 3).  
The proportion of abnormalities was calculated by adding the values obtained from the two 
replicate scores (1000 binucleates were evaluated from each of two slides for a total of 2000 
binucleates per study participant). The total number of binucleates with abnormalities was then 
divided by the total number of binucleates scored.  
 
Data analysis: 
The OncoScan Console 1.0 software was used to determine that the experimental processes met 
or exceeded vendor established quality control standards. The OncoScan Nexus express software 
was used to identify CNAs, LOH, and somatic mutations in the tumor samples. Statistical 
Pearson’s correlation comparisons between tumor CNAs and peripheral blood chromosomal 
instability were completed using the R programming environment (R Development Core Team, 
2011). 
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                 Figure 9: Log 2 ratio and B allele frequency plots for sample 2005. 
CNAs were detected for chromosomes 15 (a loss at 15q); 16 (loss); 18 (a loss [monosomy]) and 20 (a gain [trisomy]). 
 The tumors were estimated to be present in approximately 70% of the cells evaluated. 
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Results 
 
     Tissue amenable for use in the OncoScan array was available for 14 of the 17 
participants who provided consent to have analyses completed for their tumor specimens, 
with three cases having an insufficient amount of residual tissue containing tumor that was 
available for assessment in this pilot study. The amount of DNA required for the OncoScan 
assay was successfully obtained from 11 of these 14 tumor tissues, with the cases having 
an insufficient amount of tumor all being derived from fine needle aspirates. Of the 11 
cases for which DNA was successfully obtained, a total of 10 specimens yielded results 
that could be interpreted, with one sample having an array result that could not be 
unequivocally evaluated (possibly due to tumor heterogeneity and/or DNA degradation). 
One of these 10 tumor specimens was from a woman who died within 2 years following 
the initiation of chemotherapy (case 2001).  
 
     The specimens that were evaluated were all obtained from participants who were 
diagnosed at early stage BC (I-IIB). The mean age of the participants was 50 years old.  
The age, race, and tumor characteristics of the participants from whom the 10 specimens 
were evaluated using OncoScan are summarized in table 17. 
 
     Summaries of the CNAs, including amplifications, and the somatic mutations occurring 
in each patient are shown in tables 2-4. CNAs were detected in all of the 10 breast tumor 
tissues evaluated, with the number of events varying from tumors to tumors (Table 18). 
Genome-wide CNAs for each patient, and collectively for the pilot study cohort, are shown 
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in Figure 10. The most frequently observed CNAs were: Gains at 1q (70%), and 8q (70%),  
and losses at: 8p (70%), 17p (70%), 17q (60%), 18q (60 %), 13q (50%),  and 22 ( 50%). 
As expected, since all the tumors were evaluated from females, loss of Y chromatin was 
observed for all tumors (far right of Figure 10) The most commonly observed pair of 
aberrations was loss of 8p and gain of 8q. High copy gain amplifications and homozygous 
losses are summarized in Table 19. Amplifications of regions including well-known 
oncogenes were observed, such as the ERBB2, MYC, and ERBB3. Amplifications (high 
copy [at least 4 copies] gains tended to be  more frequent in HER2+ tumors (patients: 2001, 
2011, 2028 ).  Moreover, homozygous deletions of well-known tumor suppressors such as 
the RB1 were also detected.  
 
     In addition to evaluating CNAs, an assessment of targeted somatic mutations was also 
completed for the tumors (Table 20).  Somatic mutations were detected for 6 of the 9 genes 
targeted in this array. A total of 7 of the 10 tumors had mutations within the TP53 gene; 6 
had mutations in KRAS gene; 6 had mutations in the EGFR gene, 5 had mutations in the 
NRAS gene, 2 in the PTEN gene and 1 in the PIK3CA gene. Mutations involving the 
KRAS and at TP53 were found in 100% of ER+ patients, but in only in 25% of ER- patients 
(p=.03).  Also, the total number of somatic mutations detected was higher in HER2+ tumors 
(HER2+ and luminal B) than HER2 negative tumors (luminal A and triple negative) 
(p=0.04). 
 
     When CNAs were compared on the basis of the tumors’ intrinsic subtypes, significant 
differences were detected (Table 21). Gains involving chromosomes: 3 (q26.31 - q27.1); 
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10 (p11.22 - p11.21) and (q22.1);  16 (p13.3); and 22 (q13.1 - q13.2) were found in 100% 
of HER2+ tumors,  and 0% of the other three subtypes (TNBC, Lum A, and Lum 
B)(p=0.02). Also, gains at 20q13.31 were seen in 100% of the TNBC tumors, but 0% of 
the other three subtypes (p=.02). Losses at 17p13.2 were present in the two HER2+ tumors,  
the 3 Lum B tumors , and 1 out of the 2  TNBC tumors, but were not present in any of the 
three  Lum A tumors (p=0.03).  
 
As expected, ERBB2 was amplified only in HER2+/Luminal B tumors. However, the 
amplification was not detected in 2 out of the 5 HER2+/Lum B patients (Patients 2001 & 
2021). Tumors were also subdivided based on their estrogen receptor (ER) status. Losses 
involving chromosomes 12 (q13.13); 15 (q24.1 - q24.2) & (q24.3 - q25.1); and 17 (q21.32 
- q21.33) & (q24.2 - q24.3) were present in 75% of patients with ER- status, but in none of 
the ER+ tumors (p= .03).  
 
 
     The tumors included in this study were determined to be either grade 2 or grade 3. 
Significant differences in the CNAs present in the grade 2 compared to grade 3 tumors 
were detected, with losses  involving the proximal short arm of chromosome 4 (4p14; 4p13; 
and/or 4p12), the proximal short arm of chromosome 7 (7p11.2), and the proximal long 
arm of chromosme 17 (17q12) being present in 75% of the grade 3 tumors, but in none 
(0%) of the grade 2 tumors (p=0.03). Moreover, when groups were compared based on the 
stage of the tumor, gains at 20q13.31 were found in 100% of stage I tumors, but in none 
(0%) of  the stage II (A or B) tumors (p=0.02). In addition, high copy gains at 8p11.22-
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p11.21 were seen in 100% of stage IIB tumors, but in none  (0%) of the lower stage tumors 
(I & IIA)(p =0.02), suggesting that this finding is associated with (or acquired in) more 
advanced tumors. 
 
      
     Comparisons were also completed to determine if baseline peripheral blood 
chromosomal instability levels were correlated with the CNAs or somatic mutations 
present in the women’s tumors.  While a trend of an association between MNF in PBCs 
and tumor mutations, the percent of the tumor genome changed, and tumor cells with 
amplification of MYC was observed, none of these associations were significant. A 
significant association was between MN and homozygous loss (p =.04) . (Table 22) 
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Table 17: Participants ‘ demographic and tumor characteristics. 
 
Subject ID Age Race  Grade Stage ER+ PR+ HER2+  Subtypes 
         
   2001 56 AA 2 IIB N N Y HER2 + 
   2005 51 AA 2 I N N N Triple negative 
   2010 41 AA 2 IIA Y Y N Luminal A 
   2011 41 AA 2 IIB Y Y Y Luminal B  
   2012 63 C 3 IIA Y N N Luminal A 
   2018 52 AA 2 IIA Y Y N Luminal A 
   2021 58 AA 3 IIA Y Y Y Luminal B 
  2026 47 AA 2 IIA N N Y HER2 + 
  2028 43 C 3 IIA Y N Y Luminal B 
  2031 48 C 3 I N N N Triple negative 
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Table 18. Number of CNAs in tumors 
 
Patient Gains 
High copy gains 
(4 or more) 
1 copy  
 Loss  
Homozygous  
        Loss 
Total 
CNA 
%  Genome  
   Changed         MNF 
2001 29        38   19 2   88   31.73 0.034 
2005 1        0   7 0   8 6.42 0.039 
2010 2        1   5 1   9   10.24 0.031 
2011 11        10   17 0   38    13.68 0.049 
 2012* 16        0   25 0   41     44.63 0.044 
  2018 6        13   16 0   35     25.16 0.061 
2021* 3        1   10 2   15   22.4 0.039 
 2026* 18        3   14 0   35     26.97 0.063 
 2028* 4        14   11 0   29     10.47 0.067 
 2031* 18        5   19 0   42      45.96 0.064 
 
* Tumors demonstrated patterns consistent with tumor heterogeneity. 
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Figure 10: Copy number alterations (CNAs) in the 10 tumors evalauted. 
(Red) indicates loss & (Blue) indicates gain. The uppermost plot shows the composite of findings observed in all participants. The lower plots 
show the findings for each tumor (identified by study participant number).
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Table 19: Amplifications and homozygous losses occurring in tumors 
 
ID  HCG*     Range of HCG Important Oncogenes included  Homozygous    
loss 
chr/gene 
2001 38 (4-9 copies) 6 copies of MYC, 4 copies of ERBB3, 5 
copies of RAD5IB, 4 copies of 
MAPK13 &14 
2 RB1 
2005 0   0  
2010 2 4 copies 4 copies of HORMAD1  1 1p13.2 
2011 10 (4-8 copies) 6 copies of ERBB2 0  
2012 0   0  
2018 13 (4-23 copies) 4 copies MYC , 13 copies CCND1 0  
2021 1  4 copies MYC 2 17p12, 
17p13.1 
2026 3 (4-10 copies) 10 copies of ERBB2, 4 copies MYC 0  
2028 14 (4-11 copies) 11 copies of ERBB2 0  
2031 5 (4-7 copies) 4 copies MYC 0  
 
 
* HCG= High copy number gain  
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Table 20: Mutations detected in tumors 
 
Patient Type  High confidence  
 
2001 Missense KRAS 
   
2005 None None 
   
2010 Missense NRAS, EGFR, KRAS, TP53 
   
2011 Missense NRAS, EGFR , KRAS, TP53 
 Nonsense PTEN 
 In-frame EGFR  
 Deletion in 
Frame  
EGFR 
   
2012 Missense TP53 
   
2018 Missensse KRAS, TP53 
   
2021 Missensse NRAS, TP53 
   
2026 Missensse NRAS, PIK3CA, EGFR, KRAS, TP53 
 Frame-shift PTEN 
   
2028 Missensse NRAS, EGFR, KRAS, TP53 
   
2031 Missensse EGFR, TP53 
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Table 21 : Significant CNAs detected in tumors based on subgroup comparisons.  
 
Chromosome Event Frequency of occurrence in 
the prominent group 
Frequency in other groups p-value 
3 (q26.31 - q27.1) Gain 100 % of HER2+  0% in (TRNG, Lum A, & Lum B) 0.02 
10(p11.22 - p11.21) Gain 100 % of HER2+  0% in (TRNG, Lum A, & Lum B) 0.02 
10 q22.1 Gain 100 % of HER2+  0% in (TRNG, Lum A, & Lum B) 0.02 
22(q13.1 - q13.2) Gain 100 % of HER2+  0% in  (TRNG, Lum A, & Lum B) 0.02 
16 p13.3 Gain 100  % of HER2+  0%  in (TRNG, Lum A, & Lum B) 0.02 
     
20q13.31  Gain 100% of TRNG 0 % in (HER2+, Lum A, & Lum B) 0.02 
     
17p13.2  Loss 85% of(TRNG,HER2+,Lum B) 0% of Lum A 0.03 
     
17p13.2  Loss 100% of (HER2+ & Lum B) 20% of (TRNG and Lum  A) 0.05 
     
12 q13.13 Loss 75% of ER- 0% of ER+ 0.03 
15 (q24.1 - q24.2)  Loss 75% of ER- 0% of ER+ 0.03 
15 (q24.3 - q25.1) Loss 75% of ER- 0% of ER+ 0.03 
17(q21.32 - q21.33) Loss 75% of ER- 0% of ER+ 0.03 
17 (q24.2 - q24.3) Loss 75% of ER- 0% of ER+ 0.03 
     
4 p14 Loss 75% of grade 3  0% of grade 2  0.03 
4 p13 Loss 75% of grade 3 0% of grade 2  0.03 
4 p12 Loss 75% of grade 3  0% of grade 2 0.03 
7p11.2 Loss 75% of grade 3 0% of grade 2  0.03 
17q12  Loss 75% of grade 3  0% of grade 2  0.03 
     
20q13.31  Gain 100% of stage I  0% of stage IIA &IIB  0.02 
8p11.22-p11.21  HCG 100% of stage IIB  0% of stage I & IIA 0.02 
     
17 q12  Loss 100% of Caucasians  0% of AA 0.008 
17q25.1  Gain 100% of Caucasians  14% AA 0.03 
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Table 22: Correlations between MNF in the peripheral blood  and CNAs 
and mutations in the tumor tissue 
 
Type of CAN 
 
Correlation with 
MNF 
p-value 
Gain 0.066 0.86 
>2 copy gain -0.054 0.88 
one copy loss 0.255 0.48 
Homozygous loss -0.651 0.04 
Total (CNA) 0.047 0.90 
% of genome changed 0.221 0.53 
Mutations 0.4 0.34 
Amplification of MYC 0.25 0.49 
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Table 23: Most frequently observed CNAs in patients with BC   
  
Most frequently observed CNAs References 
  
Gains at 1q (35%), 8q (35%)  , 11q (26%), and 16p (14%) Bergamaschi et al 2006 
Losses at 4q (58%), 5q(54%), 6q(43%), 8p(48%), and 14 q(48%).   
  
Gains at 1q (55%), 8q (41%), 16p (40%), 17q (28%), 20q (19%), 
and 11q (16%).  
Rennstam et al 2003 
Losses at 13q (27%), 16q (22%), 8p (18%),  
most frequent pairs: -8p/+8q, +17q/+20q, and -4q/-13q  
  
Gain at 1q (64.8%), 8q (61.4%), 17q (50.0%), 20q (33.0%), 3q 
(20.5%), 1p (17.0%), 5p (17.0%) and 15q (17%) 
Weber-Mangal et al 
2003 
Loss at 8p (19.3 %), 11q (11.4%), 16q (11.4%), 17p (11.4%) and 
18q (10.2%).  
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Discussion 
 
     The CNAs detected in the small number of tumors evaluated for this pilot study were 
consistent with previously reported findings using chromosomal banding, chromosomal array 
CGH, and/or microarray methodologies. For example, the most frequently observed CNAs 
seen in the tumors assessed in this pilot study included: Gains at 1q, 8q, and 8p, and losses in 
8p, 17p, 17q, 18q, 13q, 22q, 4p, 5q, 11q, and 16q (Figure 10). Most of these regions have also 
been recognized as areas of imbalance seen most often in BC tumors evaluated by other 
investigators (Thompson et al 2011, Bergamaschi et al 2006, Weber-Mangal et al 2003, 
Rennstam et al 2003)(Table 23). In agreement with our observations, losses at 8p and gains 
at 8q are one of the most commonly observed pairs of aberrations seen in BC tumors 
(Rennstam et al 2003), and are likely to reflect the presence of an isochromosome/isodicentric 
chromosome for the long arm of chromosome 8. 
 
            Our assessments of CNAs with tumor subtype also showed areas of agreement with 
the results of previous investigators. For example, we observed losses at 17p13.2 (which is 
located near the TP53 gene but did not include it) in 6 of the 10 tumors analyzed, but none of 
the 3 luminal A tumors showed this loss. Other investigators have also reported a higher 
frequency of 17p13.1 loss in luminal B and HER2+ tumors compared to luminal A and triple 
negative tumors. (Thompson et al 2011). 
 
     Interestingly, the tumor that was obtained from patient 2001, who died within 2 years 
following the initiation of her chemotherapy, is the only tumor evaluated that showed multiple 
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regions of high copy gains, including amplification of well-known oncogenes such as MYC, 
ERBB3, RAD5IB, MAPK13, MAPK14.  This tumor also contained a homozygous deletion 
of the RB1 gene, losses involving 8p22 and Xp21, and a gain at 10p11.2. Many of these 
aberrations have been reported to be associated with a poor outcome.  
     As expected, ERBB2 was amplified only in the HER2+ & Lum B tumors. However, 
amplification for HER2 that was detected in diagnostic testing using FISH methodology was 
not detected in 2 of the 5 tumors evaluated with the OncoScan array platform (Patients #2001 
& 2021). Tumors for patient 2021 showed high levels of heterogeneity in the microarray test. 
Thus, it is possible that the proportion of cells having amplification in the section of residual 
tissue available for evaluation was not large enough to allow for its detection above the 
“noise” present in this specimen. Indeed, the results of the Oncoscan assessment for this case 
showed at least two cell populations, with one of them being present in a low proportion of 
cells. An additional factor that might have contributed to the observed discrepancy between 
the FISH and microarray test results was the loss of chromatin from the short arm and 
centromeric region of chromosome 17, which is a finding that was noted in both discrepant 
cases. The OncoScan platform has been reported to allow for the detection of false positive 
HER2 FISH results, the latter of which have been observed for HER2 to control probe 
(localized to the centromeric region of chromosome 17) ratios that are greater than or equal 
to 2 due to a relative decrease in centromeric probe signals rather than in increase in HER2 
signals, which is a finding that can be undetectable in a tumor having a near-tetraploid 
complement.  Clearly, this observation requires further investigation through carefully 
designed clinical validation studies before the OncoScan platform is used for diagnostic 
testing.  
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     While the number of tumors evaluated in this study was small, the tumors analyzed 
included representatives from each of the 4 intrinsic tumor subtypes. Although preliminary, 
the results of this study suggest that the evaluation of CNAs could provide additional 
information to facilitate the recognition of tumor subtypes. For example, gains at 3q26.31 to 
3q27.1; 10q22.1; 16p13.3; and  22q13.1 to 22q13.2 were found only in two patients, both of 
whom were both HER2+. To our knowledge, none of these CNAs have been previously 
reported to be specifically associated with HER2+ tumors.  Our observation of gains of 
20q13.31 has also been detected in BC tumors by other investigators (Weber-Mangal, et al, 
2003; Thompson, et al.,2011). However, the association of gains of 20q with tumor type is 
not consistent, with our data showing this finding only in patients diagnosed with TNBC, 
while other investigators have reported associations between gains for 20q in HER2 + and 
Lum B tumors (Thompson et al. 2011). Thus, the diagnostic and prognostic relevance of this 
finding appears to be limited.  
 
        No clear trend for an association between MNF in the peripheral blood and copy number 
alterations or mutations in the tumor was detected. The only significant correlation observed 
was between MN in PB and homozygous loss in the tumor ( r= -0.6 , P=0.04) Table (6). 
However, this observation is based on only three homozygous deletions. Thus, this result 
should be interpreted with caution and the potential associations confirmed using a larger 
sample size.  
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     In conclusion, the results of this “proof of principle” study support the use of the OncoScan 
genome-wide array for assisting with the recognition of differences between tumors. 
However,  our data are too preliminary to determine if the CNAs recognized will lead to 
improvements in categorization or prognostication of BC tumors. Also, our study results 
showed no clearly significant associations between MNF in PB and any of the CNAs changes 
in the tumor, with the exception of homozygous deletions.  
     Through our future evaluation of a larger number of tumor specimens we hope to be able 
to answer the following questions: Could CNAs in the tumor tissue associate with CNAs and 
methylation patterns in WBCs? Do CNAs in the tumor tissue associate with the acquisition 
and/or persistence of adverse side effects related to chemotherapy? Could alterations observed 
in peripheral blood cells be used as early detectors of carcinogenesis in the tumor tissue? The 
use of WBCs as early detectors of cancer or as early predictors of an outcome is a concept 
that is worthy of more investigation.  
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Chapter 5 
 
Conclusions 
 
     The primary goal of the current study was to investigate the biological basis for the 
development of  psychoneurological symptoms (PNS) associated with chemotherapy, or the 
cancer itself, in women treated for breast cancer (BC). A longitudinal study was designed to 
investigate chromosomal/epigenetic changes in peripheral blood cells collected from women 
with BC at 5 time points and to examine the role of chromosomal alterations present in the 
tumor tissue at baseline. 
The following conclusions were attained for the study aims that were examined. 
Aim A) Determine the frequency of acquired chromosomal instability present before 
and following treatments and investigate its relationship to the 
development/persistence of PNS. 
 
To date, micronuclei frequencies (MNF) have been scored for a total of 73 women at 4 times 
points, with  43 of these women also having data available for a fifth time point (2 year follow-
up).  The data presented in this dissertation included only the 4 time points that have been 
statistically analyzed. The final optimized statistical model identified 8 variables that had a 
significant predictive association with MN/cytome abnormality frequencies. These variables 
included: 
(1) The time point at which the specimen was collected (p<0.0001) 
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(2) The type of chemotherapy treatment (p=0.0463) 
(3) Exposure to radiotherapy (p=0.0004) 
(4) Race (p=0.0037) 
(5) Having a luminal B tumor categorization (p=0.0182) 
(6) Having a triple negative tumor categorization (p=0.0446) 
(7) Total perceived stress levels (p=0.0123) 
(8) Cognitive flexibility domains (p=0.0238) 
 
     Decreases in MNF were observed 1 year following treatment, but did not return to baseline 
levels. At 2 years following chemotherapy, the preliminary results including a subset of 
women at time point 5 shows that MNF declined following the completion of all treatments. 
However, women showed variability, with levels of MN returning to baseline in a subset of 
women but remaining high in other women. 
 
Aim B) Determine genome-wide epigenetic changes present at baseline and following 
chemotherapy to determine if methylation alterations are induced in peripheral blood 
cells following treatment.  
 
     To date, DNA methylation data has been collected for 69 women (at time points 1 & 2), 
and for 57, 45, and 10 women at time points 3, 4 and 5 respectively. The present dissertation 
includes results that have been statistically analyzed for 67 women before and during 
chemotherapy (T1 & T2). The following results have been concluded: 
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1) The results indicate that epigenetic changes associated with chemotherapy are acquired in 
peripheral blood. 
2) A total of 1265 sites showing significant differential methylation after chemotherapy were 
detected at (FDR= 0.01 and >10% mean within pair difference). These sites included CpGs 
located within genes that are involved in the cell cycle, transcription regulation, cell death, 
signal transduction, neurogenesis, and in  immune response.  
3) Acquired decreases in methylation were more frequent than acquired increases in 
methylation. 
4) Acquired alterations in DNA methylation were distributed across different genomic 
sequences, with the majority of changes occurring in the open sea sequences. 
 
Aim C) Detect CNV present in BC tumor tissue and determine its relationship to 
peripheral blood MNF and methylation patterns at baseline. 
 
     Only 10 samples were included in this preliminary investigation. Not surprisingly, due to 
the small sample size, no clear associations were detected between MNF in blood and CNVs 
in tumors.   However, the CNVs detected in the small number of tumors analyzed using the 
new OncoScan microarray platform were consistent with those previously reported in breast 
cancer tumors,  thereby confirming that the genetic make-up of our study participants’ tumors 
are representative of  those observed in larger groups who were evaluated  using alternative 
methods (classical chromosomal banding, chromosomal array CGH, and/or other microarray 
platforms).  
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     Overall, our results support the primary hypothesis of this study, which states that in 
response to chemotherapy, biological changes arise in somatic tissue (PBCs) leading to 
genomic and/or epigenetic alterations that potentially contribute to PNS. Each of these 
genomic/epigenetic factors, acting either singly or in concert, could contribute to the 
development/ persistence of PNS since they would provide a means for “remembering” the 
biological effects after chemotherapy and have plasticity to explain responsiveness to 
environmental exposures (as well as G x E interactions). They also have the potential for 
reversibility, with the latter attribute being important for the potential development of 
therapeutic interventions. 
     This data also indicates the feasibility of using peripheral blood to assess and monitor an 
individual’s soma-wide cellular response to different types of treatment regimens. Further 
investigation and continuation of this study, including all patients at all time points, could 
provide insight about the biological changes underlying a person’s propensity to develop 
adverse side effects following chemotherapy, including but not limited to PNS. Ultimately, 
these types of studies could lead to the development of tests to identify women most at risk 
for acquiring cancer or cancer treatment-related side effects and could lead to “personalized 
medicine” approaches that might improve the quality of life for BC survivors. 
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                                                                  Chapter 6 
 
 
 
Methylation patterns in fetuses in fetu having disorganized development compared to 
those in their identical liveborn triplet  
 
     Fetuses in fetu (FIF) is a rare condition in which the growth of a twin/triplet erroneously 
occurs within the body of a co-twin/triplet. The incidence is estimated to be 1/500,000 births 
(Hoeffel et al., 2000). While the term fetus in fetu has been reported by Meckel in 1800, and 
the first case was been cited in 1809 by Young, a specific diagnostic criteria to distinguish it 
from teratoma was not developed until 1935 when Willis (Willis, 1935) defined the diagnosis 
of FIF by the presence of a vertebral column, which is often surrounded by other organs. In 
1956, Lord suggested that in addition to the presence of the vertebral axis, an appropriate 
arrangement of other organs and limbs is required. The majority of cases are found to occur 
as an abdominal mass (Hoeffel et al., 2000). However, reports of FIF present in the sacrum, 
pelvis, liver, lungs, spleen, lymphnodes, pancreas, adrenal gland, scrotum and in the cerebrum 
have also been described (Gangopadhyay et al 2010, Heuer et al 2008, Escobar et  al, 2008). 
 
     A mechanism for FIF is that they arise from the inclusion of a diamniotic monochorionic 
monozygotic twin in its co-twin due to the unequal division of the inner cell mass during 
embryogenesis (Lord, 1956, Beaudoin et al 2004). An alternative theory, termed the teratoma 
theory, states that the mass found in the fetus is a highly-organized, well differentiated 
teratoma (Magnus et al, 1999; Gilbert-Barness et al., 2003). 
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To gain insight about the embryonic origin of FIF Miura et al (2006) completed genotyping 
studies for two different cases of FIF and also looked at the methylation status at the human 
IGF2-H19 locus. They concluded that the genotypes of both cases of FIF were identical to the 
genotypes of the host infant, providing support for the monozygotic twin theory of 
development.  They further conjectured that the implantation of the FIF occurred during the 
process of methylation establishment in the first case (based on differing patterns of 
methylation in the multiple clones evaluated), while it happened after the establishment of 
methylation in the 2nd case.  
 
     In 2012, Huddle et al published a case report on rare intraventricular fetuses in fetu.  The 
case was diagnosed following both Willis’ and Lords’ criteria. Two fetiform structures were 
connected to the host’s circulation by a vascular pedicle. Both masses were anencephalic and 
had a vertebral column with well-formed limbs. The two fetuses had other organs including 
CNS, gastrointestinal, and genitourinary tissues along with other less commonly observed 
organs such as the thymus, salivary glands, tooth buds, and adnexal structures. The organs 
were in a relatively correct anatomic arrangement to one another. Karyotyping and genotyping 
(using a SNP array analysis) on tissues obtained from the two fetuses and the host confirmed 
that the three structures were genetically identical females with a normal chromosomal 
complement.  Thus, this case supports the monozygotic twin theory.  These FIF also provide 
a unique opportunity to recognize genes that undergo methylation alterations during 
embryogenesis since they share identical genotypes, albeit in very different development 
environments.  Therefore, the primary aim of this study was to determine the genome-wide 
DNA methylation patterns in the two fetuses in fetu and to compare those patterns to the 
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patterns seen in their genetically identical host triplet, the latter of whom showed normal 
development other than the brain malformations that resulted from the management of the 
FIF (Huddle, 2012). 
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Materials and Methods 
 
Subjects and sample collection: 
The patient was a female child of Vietnamese ancestry who was initially ascertained following 
an ultrasound study at 37 weeks’ gestation, the latter of which showed dilated lateral ventricles 
and a possible aqueductal stenosis.  At birth, a head CT showed significant ventriculomegaly 
with a midline intraventricular sof-tissue mass having ossified stuctures suggestive of a 
fetiform mass.  At 3 months of age, the child presented with neurological symptoms that 
necessitated  the need for a craniotomy to remove the FIF masses.  More details about the 
clinical findings in the patient and the fetus in fetu are provided in the case report by Huddle 
et al, (2012).   At the time of surgery, a blood sample was collected from the child (host), and 
biopsies were collected from the FIF tissues. Tissues from the FIF were immediately 
established in culture, using standard procedures, to allow for the completion of the requested 
chromosomal studies. Genomic DNA for the FIF was extracted from the cells established in 
monolayer cultures using the Puregene DNA Isolation Kit (Qiagen) according to the 
manufacturer’s methodology. Genomic DNA was isolated directly from the whole blood 
sample collected from the host child using this same procedure (Puregene DNA Isolation Kit 
by Qiagen).  Requests to collect a skin biopsy from the host child (to allow for a more direct 
comparison of tissue types between the FIF and their liveborn triplet) were unsuccessful.  
Therefore, to assist with recognizing methylated regions that varied due to tissue-type 
differences, DNA was also isolated from the fibroblast-like cells from an amniotic fluid 
specimen. Also, to allow for comparisons of the methylation patterns seen in the FIF to those 
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present in multipotent cells, DNA was isolated from 3 unrelated breast adipose-derived 
mesenchymal stem cells (bASC1, bASC2, bASC3)(Sachs, et al., 2012)  
 
Genome-wide DNA methylation pattern: 
      The 450K HumanMethylation Chip (Illumina) was used for determining genome-wide 
DNA methylation patterns in: (1) the fetuses in fetu;  (2) the host child (peripheral blood); (3) 
3 multipotent breast adipose-derived stromal cell lines; and (4) cultured cells from an amniotic 
fluid specimen. Following bisulfite conversion, the genomic DNA was hybridized to the 450K 
HumanMethylation Chip according to the manufacturer’s protocol (Illumina).  
 
Data visualization and statistical analysis: 
     The Genome Studio Methylation Module (Illumina) and R (R 2.15.1) were used for data 
visualization and statistical analysis.  The minfi package from R was used for data 
normalization, Pearson’s correlations estimation, and for Bean and density plot creations.  To 
determine the specific CpG sites that were differentially methylated between the child and the 
two FIF the following strategy was followed: for each sample, bead level data were read into 
the R programming environment. After excluding beads having a negative or zero intensity 
in either the red or green channel, raw signal intensities for the Methylated and Unmethylated 
Infinium Type I designed beads were retained and for Infinium Type II designed beads, 
proportion methylated was calculated as =(Red intensity)/(Red intensity + Green intensity) 
=[0,1]. Prior to applying the logit transformation, any  values equal to 0 were imputed to 
be 0.0001 while  values equal to 1 were imputed to be 0.9999. Thereafter, a logit 
transformation was applied to the  values to promote normality.  
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     For Infinium design type I beads, the logarithm of the signal intensity was modeled using 
an analysis of variance (ANOVA) where probe type (Methylated or Unmethylated), subject 
(Child, FiF), and their interaction was included as fixed effects in the model. The p-values 
from the two independent ANOVA models were then combined using Fisher’s method for 
combining p-values. The false discovery rate was estimated using the combined p-values 
based on the Benjamini and Hochberg method (1995). CpG sites having both an FDR<0.01 
and a ||  0.20 were considered significant. For Infinium design type II beads, the statistical 
analysis was restricted to bead types having at least two observations in all three samples. For 
each FiF and bead type, a two-sample t-test was performed to compare the logit-transformed 
 values between group (Child versus FiF). Again, Fisher’s method was used to combine p-
values resulting from the two independent t-tests and then Benjamini and Hochberg’s method 
was used to estimate the false discovery rate.  
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Results 
 
 
     Bean plots for the beta values are shown in Figure 11 for each of the 7 specimens.  
The greatest level of variation was observed for hypermethylation states. While the 
methylation patterns of the 2 genetically identical FIF closely resembled one another, their 
patterns (especially hypermethylation) varied from those observed for the other specimens, 
showing patterns that more closely resembled those of the multi-potent stem cells, than their 
genetically identical “host” triplet, or the tissue comparable amniotic fluid specimen. 
Interestingly, the multi-potent adipose-derived stromal cells that were derived from 3 
unrelated individuals showed similar patterns, suggesting that the methylation status of these 
cells was more closely associated with their multi-potent characteristic than their genotype.  
 
The density of the beta values is shown in Figure 12 for each specimen. The samples 
tend to cluster into 3 groups: (1) the child and amnio case (highest density of hypermethylated 
loci); (2) the fetuses in fetu (mid-group); and (3) the multi-potent adipose-derived stromal 
cells (lowest densities for hypermethylated sites) 
 
Genome-wide methylation states were highly correlated between the fetuses in fetu (Figure 
13 A). However, the methylation states of the fetuses in fetu more highly correlated to the 
patterns of the multi-potent adipose-derived stromal cell lines than to those of the host child 
or the amniotic fluid case (Figure 13).   
A genome-wide sample and locus cluster analysis confirmed the overall similarity in 
methylation patterns between the genetically identical (FIF), and the similarity between the 
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stem cells (dendograms on right based on complete data set). The observation that the host 
child was more closely related to the amniotic fluid case than the fetuses in fetu, suggests that 
the observed patterns reflect factors other than just genotype or tissue type. (Figure 14) 
     Over the 485,764 sites interrogated, clusters of similar patterns were observed that were: 
(A) consistent for the FIF and host child, but not the other specimens (likely to be genotype 
driven); (B) limited to the FIF; (C) common for the FIF and the multi-potent cells but not the 
child/amniotic fluid cells (influenced by environmental/developmental cues); (D) distinct for 
the multi-potent cells; (E) distinct to peripheral blood (shown) or amniotic fluid cells (not 
shown);  or (F) similar across all specimens. The results of a cluster analysis that was 
completed for the entire data set 9 (Figure 14) confirmed the similarity in patterns between 
the FIF, with the greatest variation in patterns being observed between the genetically 
identical host child blood specimen and the FIF samples.  
 
     An analysis to identify specific CpG sites that were differentially methylated in the FIFs’ 
and the child’s genomes, based on the Infinium design type I beads, revealed 12,187 
significantly differentially methylated CpG sites (using a false discovery rate [FDR] <0.01 
and a ||  0.20). For the Infinium design type II beads, a total of 56,090 CpG sites showed 
significantly different methylation values (FDR<0.01 and a ||  0.20).  
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                     Hypomethylation                                                                                  Hypermethylation 
                                                                                                    -values 
 
 
Figure 11: Bean plots for FIF: Bean plots are shown for the beta values for each of the 7 
specimens, with the mean beta values being represented as a vertical line for each case. The 
greatest level of variation was observed for hypermethylation states, with the multipotent 
adipose-derived mesenchymal stem cells (bASC1, bASC2, bASC3 shown in green) having 
similar patterns between specimens derived from unrelated individuals.  Also, the 
monozygotic fetus in fetu specimens (FIF 1 [purple]; FIF 2 [orange]) had similar patterns. 
However, despite being genetically identical, the fetuses in fetu had distinct patterns from 
those observed in the host child (aqua) 
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                    Hypomethylation                                                                 Hypermethylation 
 
 
 
Figure 12: Density plots for FIF: The density of the beta values is shown for each 
specimen. For hypermethylation densities, the samples tend to cluster into 3 groups: (1) the 
child and amnio case (highest density of hypermethylated loci); (2) the fetuses in fetu (mid 
group); and (3)  the stem cells (lowest densities for hypermethylated sites) 
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A) 
 
B) 
         
C) 
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D) 
 
                  
 
 
Figure 13: Correlations for FIF. Genome-wide methylation states were highly correlated 
between the fetuses in fetu (A). When comparing the methylation states of the fetuses in fetu 
to those of the other specimens, the following trend toward correlations of locus-specific 
sites was observed:  Stem cells (B) correlation > Host child (C) or Amnio case 
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                               (a)                                                                 (b) 
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 Figure 14: Heat maps for FIF 
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Heat maps showing examples of methylation patterns for subsets of 30 loci (columns) for each of the 
specimens (rows). Each square in the heat map shows the relative level of methylation for a specific 
site evaluated (values range from 0 to 1, with bright green corresponding to sites that are 
hypomethylated, while bright red corresponds to sites that are hypermethylated). Over the 485,764 
sites interrogated, clusters of similar patterns were observed that were: (A) consistent for the FIF and 
host child but not the other specimens (likely to be genotype driven); (B) limited to the FIF; (C) 
common for the FIF and the stem cells but not the child/amnio (influenced by 
environmental/developmental cues); (D) distinct for the stem cells; (E) distinct to peripheral blood 
(shown) or amniocytes (not shown) or (F) similar across all specimens. The dendograms on the right 
show the cluster analysis results for the specimens based on the entire data set [not the subset of 
examples shown to illustrate the types of variation observed].  
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Discussion 
 
            Here, we present the first case of fetus/fetuses in fetu for which a genome-wide 
analysis of methylation patterns has been determined.  The only other group to report 
methylation patters in FIF is Miura et al. (2006), who analyzed methylation patterns between 
the host/FIF duos for 2 kindreds using a targeted assessment of a single gene that is known to 
be differentially methylated (imprinted).  Based on their results, they concluded that the 
embryonic timing of the  implantation of the FIF could impact the methylation pattern of 
genes in the FIF. 
 
     Epigenetic reprogramming is a critical process during the normal development of an 
embryo.  Upon fertilization, global demethylation takes place in whole genomic sequences 
except for imprinted loci, which are maintained. This erasure is followed by a whole genome 
de novo methylation. (Reik et al., 2001, Li, 2002, Owen and Segars, 2009) Since there is a 
lack of studies investigating human embryos, most of the findings in embryogenesis come 
from studies of mouse embryos.  In mice, it has been shown that the paternal genome 
undergoes demethylation rapidly and reaches the lowest levels of methylation before the two-
cell embryo stage (Haaf. T, 2006). However, the maternal genome imprints are maintained 
up to the two-cell embryo stage, then  the methylation marks start to gradually drop until after 
the eight-cell embryo stage, when both paternal and maternal become equally demethylated 
(Haaf. T,  2006 ). Genome-wide de novo methylation happens preferentially in the inner cell 
mass o the blastocyst-stage embryos, thereby allowing for the establishment of the somatic 
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methylation patterns in the embryo’s cells, which then differentiate to various embryonic 
lineages (Haff , 2006, Mayer et al 2000a, Reik et al 2001, Dean et al. 2001, Li, 2002). 
 
      Given that FIF is thought to originate in the blastocyst-stage of embryogenesis as a result 
of the unequal division of the inner cell mass, which is thought to be a stage that is important 
for epigenetic reprogramming (Lord, 1956, Beaudoin et al 2004; Haaf, 2006), studies of 
methylation patterns in FIF cases could provide insight regarding embryonic methylation and 
development.  In this study, we showed that the greatest level of variation in methylation 
patterns between the FIFs and the host trio involved hypermethylation states. The three multi-
potent adipose-derived stromal cells showed the lowest density of methylation at 
hypermethylated sites, followed by the two FIF,  then  the amniotic fluid cells and then the 
genetically identical FIF host child.  
 
     A shortcoming of this study was our inability to study a similar tissue type (skin) from the 
host child for comparison to the patterns seen in the fibroblasts from the FIF.  However, the 
methylation patterns observed suggest that the differences reflect changes beyond those 
related to tissue-specific or genotype specific findings since the amniotic fluid cell patterns 
were more closely related to the host child then the FIFs (similar phenotype [normal], but 
different genotype and cell type). The observation of a higher density of hypermethylated sites 
in the host child compared to the FIF is consistent with a lack of the FIF specimens to complete 
the normal re-establishment of methylation patterns during embryogenesis. The data also 
suggest that epigenetic changes acquired during development are more heavily influenced by 
embryonic environmental cues than the developing embryo’s genotype since the genetically 
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identical FIF and host child showed the greatest patterns of divergence. This is not surprising 
since establishing epigenetic imprints in the fetus is very critical during the formation of the 
blastocyst and it is known that the first trimester of pregnancy is very sensitive to 
environmental influences. Nonetheless, there were subsets of genes that did appear to be 
closely related to genotype, with other subsets being identified that had consistent methylation 
patterns across all specimens.  
 
     The observation that the methylation patterns for the multi-potent adipose-derived stem 
cells were more closely related to the FIF specimens than the other specimens is also 
interesting. One could speculate that the FIF cells retain their multi-potent capacity due to a 
failure to “silence” genes that would typically be methylated. The “cues” necessary for 
initiating these methylation alterations may involve microenvironments from the surrounding 
cells, rather than being strictly encoded through the organism’s genome. A full assessment of 
the individual sites demonstrating differential methylation may provide clues as to genes/gene 
networks that are most closely related to methylation status to allow for normal 
embryogenesis to proceed. 
 
     In summary, further whole genome methylation studies of rare cases of fetus in fetu could 
provide valuable insight about epigenetic patterns that are acquired during human 
embryogenesis, as well as the influences those patterns play in directing tissue/morphological 
development.  
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